
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="67D7128F89B720F31C128F00255D1BA2.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="clinhemint">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Clinical Hematology International">
<meta name="citation_title" content="Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches">
<meta name="citation_author" content="Viviana Cortiana">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy">
<meta name="citation_author" content="Harshitha Vallabhaneni">
<meta name="citation_author_institution" content="Apollo Institute of Medical Sciences and Research, Hyderabad, India">
<meta name="citation_author" content="Jenna Ghazal">
<meta name="citation_author_institution" content="Kalamazoo Valley Community College, Kalamazoo, Michigan, USA">
<meta name="citation_author" content="Kennedy Itodo">
<meta name="citation_author_institution" content="Nigerian Institute Ffor Trypanosomiasis Research, Jos, Nigeria">
<meta name="citation_author" content="Taha Kassim Dohadwala">
<meta name="citation_author_institution" content="David Tvildiani Medical University, Tbilisi, Georgia">
<meta name="citation_author" content="Chandler Park">
<meta name="citation_author_institution" content="Norton Cancer Institute, Louisville, KY, USA">
<meta name="citation_author" content="Yan Leyfman">
<meta name="citation_author_institution" content="NewYork-Presbyterian Hospital, Brooklyn, NY, NY, USA">
<meta name="citation_publication_date" content="2025 Aug 7">
<meta name="citation_volume" content="7">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="24">
<meta name="citation_doi" content="10.46989/001c.142956">
<meta name="citation_pmid" content="40786240">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/pdf/chi_2025_7_3_142956.pdf">
<meta name="description" content="Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, ...">
<meta name="og:title" content="Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12334995">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.46989/001c.142956"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/chi_2025_7_3_142956.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12334995%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12334995/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12334995/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-clinhemint.jpg" alt="Clinical Hematology International logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Clinical Hematology International" title="Link to Clinical Hematology International" shape="default" href="https://chi.scholasticahq.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Clin Hematol Int</button></div>. 2025 Aug 7;7(3):24–35. doi: <a href="https://doi.org/10.46989/001c.142956" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.46989/001c.142956</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Clin%20Hematol%20Int%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Clin%20Hematol%20Int%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Clin%20Hematol%20Int%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Clin%20Hematol%20Int%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cortiana%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Viviana Cortiana</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Viviana Cortiana</span></h3>
<div class="p">
<sup>1</sup>Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy</div>
<div>Conceptualization, Methodology, Investigation, Writing – original draft, Project administration</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cortiana%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Viviana Cortiana</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vallabhaneni%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Harshitha Vallabhaneni</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Harshitha Vallabhaneni</span></h3>
<div class="p">
<sup>2</sup>Apollo Institute of Medical Sciences and Research, Hyderabad, India</div>
<div>Conceptualization, Methodology, Investigation, Writing – original draft, Visualization</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vallabhaneni%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Harshitha Vallabhaneni</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ghazal%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Jenna Ghazal</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Jenna Ghazal</span></h3>
<div class="p">
<sup>3</sup>Kalamazoo Valley Community College, Kalamazoo, Michigan, USA</div>
<div>Formal Analysis, Investigation, Writing – original draft, Visualization</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ghazal%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jenna Ghazal</span></a>
</div>
</div>
<sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Itodo%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Kennedy Itodo</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Kennedy Itodo</span></h3>
<div class="p">
<sup>4</sup>Nigerian Institute Ffor Trypanosomiasis Research, Jos, Nigeria</div>
<div>Methodology, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Itodo%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kennedy Itodo</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kassim%20Dohadwala%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Taha Kassim Dohadwala</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Taha Kassim Dohadwala</span></h3>
<div class="p">
<sup>5</sup>David Tvildiani Medical University, Tbilisi, Georgia</div>
<div>Formal Analysis, Visualization</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kassim%20Dohadwala%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Taha Kassim Dohadwala</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Park%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Chandler Park</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Chandler Park</span></h3>
<div class="p">
<sup>6</sup>Norton Cancer Institute, Louisville, KY, USA</div>
<div>Writing – review &amp; editing, Resources, Supervision</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Park%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chandler Park</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leyfman%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Yan Leyfman</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Yan Leyfman</span></h3>
<div class="p">
<sup>7</sup>NewYork-Presbyterian Hospital, Brooklyn, NY, NY, USA</div>
<div>Conceptualization, Writing – review &amp; editing, Resources, Supervision</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leyfman%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yan Leyfman</span></a>
</div>
</div>
<sup>7</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="author-aff-1">
<sup>1</sup>Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy</div>
<div id="author-aff-2">
<sup>2</sup>Apollo Institute of Medical Sciences and Research, Hyderabad, India</div>
<div id="author-aff-3">
<sup>3</sup>Kalamazoo Valley Community College, Kalamazoo, Michigan, USA</div>
<div id="author-aff-4">
<sup>4</sup>Nigerian Institute Ffor Trypanosomiasis Research, Jos, Nigeria</div>
<div id="author-aff-5">
<sup>5</sup>David Tvildiani Medical University, Tbilisi, Georgia</div>
<div id="author-aff-6">
<sup>6</sup>Norton Cancer Institute, Louisville, KY, USA</div>
<div id="author-aff-7">
<sup>7</sup>NewYork-Presbyterian Hospital, Brooklyn, NY, NY, USA</div>
<div class="author-notes p">
<div class="fn" id="author-note-1">
<sup>✉</sup><p class="display-inline">These authors contributed equally to this work. Correspondence: viviana.cortiana@studio.unibo.it</p>
</div>
<div class="fn" id="author-note-2">
<sup>#</sup><p class="display-inline">These authors contributed equally to this work</p>
</div>
</div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Viviana Cortiana</span></strong>: <span class="role">Conceptualization, Methodology, Investigation, Writing – original draft, Project administration</span>
</div>
<div>
<strong class="contrib"><span class="name western">Harshitha Vallabhaneni</span></strong>: <span class="role">Conceptualization, Methodology, Investigation, Writing – original draft, Visualization</span>
</div>
<div>
<strong class="contrib"><span class="name western">Jenna Ghazal</span></strong>: <span class="role">Formal Analysis, Investigation, Writing – original draft, Visualization</span>
</div>
<div>
<strong class="contrib"><span class="name western">Kennedy Itodo</span></strong>: <span class="role">Methodology, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Taha Kassim Dohadwala</span></strong>: <span class="role">Formal Analysis, Visualization</span>
</div>
<div>
<strong class="contrib"><span class="name western">Chandler Park</span></strong>: <span class="role">Writing – review &amp; editing, Resources, Supervision</span>
</div>
<div>
<strong class="contrib"><span class="name western">Yan Leyfman</span></strong>: <span class="role">Conceptualization, Writing – review &amp; editing, Resources, Supervision</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 18; Accepted 2025 Jun 28; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<p>
This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License (4.0)</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12334995  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40786240/" class="usa-link">40786240</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, such as the International Consensus Classification (ICC) and the WHO 2022 classification, have incorporated molecular and cytogenetic markers to improve the stratification of risk and guide therapy. However, treatment options for high-risk MDS (HR-MDS) remain limited, with hypomethylating agents (HMAs) providing only modest survival benefits. Emerging treatments such as immune checkpoint blockade and novel targeted therapies could further improve patient outcomes. While early excitement was significant, clinical trials of the immune checkpoint inhibitors (ICIs) ipilimumab and durvalumab have produced no definitive results, highlighting the need for better patient selection and combination regimens. Emerging drugs luspatercept and imetelstat have been suggested for lower-risk MDS (LR-MDS) by promoting transfusion independence and global hematologic response. In contrast, exploratory agents such as pevonedistat, magrolimab, and sabatolimab are under further investigation for HR-MDS. The future of MDS treatment currently addresses precision medicine, in which molecular characterization guides therapeutic options. Identification of predictive biomarkers for response to targeted therapies and immunotherapies is crucial to optimize patient outcomes. An integrated, patient-centered approach combining genomics, novel therapeutics, and immunomodulation is therefore essential to address the current needs in MDS management.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Myelodysplastic Syndromes (MDS), Immune Checkpoint Inhibitors, Hypomethylating Agents (HMAs), Precision Medicine, Targeted Therapy, Hematologic Malignancies, Immunotherapy.</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms marked by ineffective hematopoiesis due to genetic and epigenetic alterations that impair cell cycling and proliferation.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1,2</sup></a> These disruptions affect hematopoietic stem and progenitor cells, resulting in multi-lineage cytopenias, dysplastic morphology, clonal genetic abnormalities, and a variable risk of progression to acute myeloid leukemia (AML).<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1,3</sup></a></p>
<p>Approximately 20,000 new MDS cases are diagnosed annually in the United States, with a five-year survival rate of about 31%.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1</sup></a> Though uncommon in individuals under 50, the incidence rises significantly with age, with a median diagnosis age of 73–76 years.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1,3,4</sup></a> Older adults often face additional challenges, including comorbidities, polypharmacy, psychosocial stressors, and age-related physiological changes affecting renal and hepatic clearance, muscle mass, and organ function.<a href="#ref-477376" class="usa-link" aria-describedby="ref-477376"><sup>2</sup></a></p>
<p>Risk factors for MDS and its precursors—clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS)—include advanced age, male gender, smoking, prior cytotoxic therapy (i.e., secondary MDS), and environmental exposures such as ionizing radiation and industrial chemicals.<a href="#ref-477377" class="usa-link" aria-describedby="ref-477377"><sup>3–5</sup></a> Inherited syndromes like Fanconi anemia, Bloom syndrome, Down syndrome, and Diamond-Blackfan anemia also increase susceptibility, along with mutations in regulatory genes.<a href="#ref-477377" class="usa-link" aria-describedby="ref-477377"><sup>3–5</sup></a></p>
<p>As highlighted by Zeidan et al {1} during his keynote at MedNews Week, tailoring therapy in MDS is particularly complex due to its underlying genetic heterogeneity.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1</sup></a> Recurrent mutations occur in genes regulating DNA methylation (e.g., TET2, DNMT3A, ASXL1), RNA splicing (e.g., SF3B1, U2AF1, SRSF2), transcription (e.g., RUNX1, CEBPA, GATA2), chromatin modification (e.g., EZH2), signaling pathways (e.g., NRAS, KRAS, FLT3), and DNA repair.<a href="#ref-477380" class="usa-link" aria-describedby="ref-477380"><sup>6–8</sup></a> Diagnostic tools such as next-generation sequencing (NGS), Sanger sequencing, and single nucleotide polymorphism (SNP) arrays are critical for identifying these alterations.<a href="#ref-477380" class="usa-link" aria-describedby="ref-477380"><sup>6–8</sup></a></p>
<p>Another challenge in MDS management is its clinical heterogeneity. To address this, various classification systems have evolved. Earlier frameworks like the French-American-British (FAB) and WHO 2001/2016 relied on morphology and blast counts. In contrast, newer systems—such as the 2022 WHO update and the International Consensus Classification—incorporate molecular and cytogenetic markers (e.g., SF3B1, del(5q), and bi-allelic TP53 mutations) to enhance diagnostic precision and prognostication.<a href="#ref-477383" class="usa-link" aria-describedby="ref-477383"><sup>9,10</sup></a></p>
<p>Dr. Zeidan also underscored limitations in traditional prognostic models like the IPSS, WPSS, and MD Anderson risk scores, which often overlook individual comorbidities and biological context.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1</sup></a> These models provide general risk assessments but lack treatment-specific predictive power. For instance, patients with therapy-related MDS often experience poorer outcomes regardless of risk category.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1</sup></a> To address this, the IPSS-M—featuring a 31-gene panel—offers refined stratification and supports more personalized treatment planning throughout the disease course.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1</sup></a></p>
<p>This commentary explores the current landscape of MDS, highlighting evolving classification systems, clinical challenges, and novel therapeutic strategies shaping the future of patient care (<a href="#attachment-296612" class="usa-link">Figure 1</a>).</p>
<figure class="fig xbox font-sm" id="attachment-296612"><h3 class="obj_head">Figure 1. Kaplan-Meier survival curves illustrating significantly poorer survival outcomes for MDS patients with TP53 mutations compared to those with SF3B1 mutations, consistent with ICC-classified prognostic expectations.<a href="#ref-477385" class="usa-link" aria-describedby="ref-477385"><sup>11,12</sup></a>.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/12334995/2ac07da08024/chi_2025_7_3_142956_296612.jpg" loading="lazy" height="705" width="795" alt="Figure 1."></p>
<div class="p text-right font-secondary"><a href="figure/attachment-296612/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="sec2"><h2 class="pmc_sec_title">2. Evolution of Response Criteria in MDS</h2>
<p>The evolution of response criteria in MDS reflects a growing understanding of the disease’s pathophysiology, progressing from basic hematologic measures to more sophisticated molecular and genetic assessments. Early response evaluations primarily relied on clinical indicators such as peripheral blood counts and transfusion dependency.<a href="#ref-477387" class="usa-link" aria-describedby="ref-477387"><sup>13</sup></a> These initial criteria, focused on hemoglobin, neutrophil, and platelet levels, provided limited insight into the biological complexity and long-term prognosis of MDS.</p>
<p>A major milestone came with the introduction of the International Working Group (IWG) criteria in the early 2000s. These refined prior definitions by distinguishing complete and partial remissions and introducing categories for hematologic improvement, including reductions in transfusion dependence. However, these criteria remained rooted in clinical and hematologic parameters without incorporating molecular features.<a href="#ref-477388" class="usa-link" aria-describedby="ref-477388"><sup>14</sup></a></p>
<p>Limitations of the IWG criteria became particularly evident in high-risk MDS, where response measures sometimes overestimated therapeutic efficacy. The 2006 introduction of the “morphologic complete remission” (mCR) concept inadvertently led to misinterpretations of drug activity. To address these challenges, an international consortium proposed updated response criteria, now known as the IWG 2020 criteria.<a href="#ref-477375" class="usa-link" aria-describedby="ref-477375"><sup>1</sup></a> These updates included the elimination of unstable mCR definitions, a redefinition of complete remission with a lower hemoglobin threshold, and the introduction of intermediate categories for less-than-complete responses. These criteria are currently undergoing validation in clinical trials.</p>
<p>Concurrently, the integration of genetic and cytogenetic markers into response assessments marked a significant advancement. Somatic mutations and chromosomal abnormalities are now recognized as essential components of disease monitoring, enabling a more nuanced understanding of clonal evolution and therapeutic response.<a href="#ref-477389" class="usa-link" aria-describedby="ref-477389"><sup>15</sup></a></p>
<p>The increasing use of minimal residual disease (MRD) monitoring through next-generation sequencing (NGS) and flow cytometry has further enhanced response assessments. These technologies allow detection of molecular disease persistence that may not be reflected in peripheral counts, offering deeper insight into treatment efficacy and disease biology.<a href="#ref-477388" class="usa-link" aria-describedby="ref-477388"><sup>14</sup></a> This shift is especially relevant with the emergence of novel agents, including immune checkpoint inhibitors and targeted therapies, which may achieve durable molecular remissions without immediate hematologic improvements.</p>
<p>Looking forward, the response criteria in MDS are expected to continue evolving alongside therapeutic innovations and advances in molecular profiling. This dynamic landscape will enable more personalized treatment strategies based on individual genetic and disease characteristics, ultimately improving prognostic accuracy and patient outcomes.<a href="#ref-477390" class="usa-link" aria-describedby="ref-477390"><sup>16</sup></a></p>
<section id="sec3"><h3 class="pmc_sec_title">Biomarkers Predictive of Treatment Response and Resistance</h3>
<p>Recent large-scale studies have elucidated the dual role of somatic mutations in MDS, not only as markers of disease prognosis but also as predictors of therapeutic response. TP53 mutations, especially biallelic (“multi-hit”) events and high variant allele frequency (VAF), represent the most adverse molecular biomarker in MDS. A pivotal analysis of over 7,000 MDS patients revealed that multi-hit TP53 mutations conferred a hazard ratio (HR) of approximately 3.7 for overall survival (OS) compared to monoallelic TP53 mutations (median OS: 8.7 versus 2.5 years; HR = 3.7; 95% CI: 2.7–5.0; p &lt; 0.001).<a href="#ref-477448" class="usa-link" aria-describedby="ref-477448"><sup>17</sup></a> Moreover, TP53 mutations are strongly associated with complex karyotypes, primary resistance to hypomethylating agents (HMAs), poor responses to chemotherapy, and rapid disease progression.<a href="#ref-477449" class="usa-link" aria-describedby="ref-477449"><sup>18,19</sup></a> These findings support the growing consensus that TP53 status, particularly its allelic state and clonal burden, should be used to stratify patients in clinical trials and guide therapeutic choices.</p>
<p>In contrast, SF3B1 mutations, found in up to 80% of MDS cases with ring sideroblasts, are associated with a favorable prognosis, longer leukemia-free survival, and robust erythroid responses to luspatercept, a first-in-class agent targeting the TGF-β superfamily pathway.<a href="#ref-477451" class="usa-link" aria-describedby="ref-477451"><sup>20,21</sup></a> These mutations are now recognized in both the 2022 WHO classification and the International Consensus Classification (ICC) as defining a distinct lower-risk MDS subtype.<a href="#ref-477454" class="usa-link" aria-describedby="ref-477454"><sup>22</sup></a> Clinical trial data from the MEDALIST and COMMANDS studies demonstrated that SF3B1-mutated patients had significantly higher rates of transfusion independence and durable hemoglobin increases with luspatercept therapy compared to wild-type cases.<a href="#ref-477452" class="usa-link" aria-describedby="ref-477452"><sup>23</sup></a> Mutations in TET2, one of the most frequently mutated genes in MDS and clonal hematopoiesis, have also been associated with increased response to azacitidine. Patients with TET2 mutations, particularly in the absence of ASXL1, had significantly higher hematologic response rates (71% versus 37%; p = 0.01) and better overall outcomes when treated with HMAs.<a href="#ref-477455" class="usa-link" aria-describedby="ref-477455"><sup>24</sup></a> This sensitivity may relate to TET2’s role in epigenetic regulation and promoter demethylation, facilitating reactivation of silenced tumor suppressor genes under azacitidine exposure. Conversely, co-mutations in ASXL1, RUNX1, or NRAS can attenuate this response, highlighting the importance of composite mutational profiling.<a href="#ref-477456" class="usa-link" aria-describedby="ref-477456"><sup>25</sup></a></p>
<p>Additional emerging biomarkers under investigation include SRSF2 and U2AF1 mutations, both spliceosome gene alterations that may predict resistance to HMA monotherapy and have been linked to clonal persistence after therapy. High VAFs in these genes often correlate with subclonal stability, suggesting limited responsiveness to single-agent treatments but potential vulnerability to splicing modulators or combination regimens.<a href="#ref-477457" class="usa-link" aria-describedby="ref-477457"><sup>26</sup></a> Incorporating these mutational markers into dynamic risk models such as IPSS-M has already improved stratification and individualization of therapy. Moreover, the advent of real-time NGS and MRD tracking is beginning to enable clinicians to adjust therapy based on evolving molecular profiles rather than static baseline characteristics. As a result, the routine inclusion of molecular biomarkers such as TP53, SF3B1, TET2, and spliceosome gene mutations in diagnostic and prognostic algorithms is rapidly becoming standard practice. These markers not only provide key prognostic information but increasingly determine eligibility for targeted agents (like eprenetapopt for TP53-mutant MDS; luspatercept for SF3B1-mutant MDS) and guide rational therapeutic combinations. The integration of biomarker-based decision-making represents a cornerstone of precision oncology in MDS.</p></section></section><section id="sec4"><h2 class="pmc_sec_title">3. Breakthroughs in Lower-Risk MDS Treatment</h2>
<p>Recent advancements in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) have significantly improved patient outcomes, bringing renewed hope to a population previously limited to largely supportive care. Given the heterogeneous nature of LR-MDS—often characterized by anemia, neutropenia, and thrombocytopenia—these breakthroughs are particularly impactful, as they target the underlying disease process rather than just mitigating symptoms.</p>
<p>Historically, treatment for LR-MDS focused on supportive interventions such as erythropoiesis-stimulating agents (ESAs) and transfusions, with curative hematopoietic stem cell transplantation largely reserved for high-risk patients. The approval of luspatercept, a first-in-class agent targeting the TGF-β pathway, marked a major shift in therapeutic strategy. The MEDALIST phase 3 trial demonstrated that luspatercept significantly improved red blood cell (RBC) transfusion independence (TI) in patients with LR-MDS, a milestone given the burden of chronic transfusions and iron overload in this population.<a href="#ref-477391" class="usa-link" aria-describedby="ref-477391"><sup>27</sup></a></p>
<p>Building on this success, the COMMANDS trial compared luspatercept to epoetin alfa, a widely used ESA, and found that luspatercept yielded superior rates of RBC TI and hemoglobin improvement. These findings firmly positioned luspatercept as a more effective option, redefining the standard of care for managing anemia in LR-MDS.<a href="#ref-477392" class="usa-link" aria-describedby="ref-477392"><sup>28</sup></a></p>
<p>Another promising agent, imetelstat, a telomerase inhibitor, is under investigation for patients with LR-MDS who have failed prior therapies. The IMerge phase 3 trial reported that imetelstat led to significant and durable improvements in hemoglobin levels, with a subset of patients achieving long-term RBC TI.<a href="#ref-477393" class="usa-link" aria-describedby="ref-477393"><sup>29</sup></a> These results suggest that imetelstat could offer a valuable alternative for patients with limited treatment options, particularly those refractory to ESAs.</p>
<p>Collectively, these studies underscore a paradigm shift in the management of LR-MDS, moving from symptomatic treatment to targeted, disease-modifying therapies. As agents like luspatercept and imetelstat gain traction, they offer not only improved efficacy but also the potential to enhance quality of life and reduce the burden of chronic transfusions. Ongoing research and real-world data will be critical to further establish their role and optimize their use in clinical practice. Continued innovation in this space holds the promise of expanding therapeutic horizons for patients with LR-MDS and improving long-term outcomes.</p></section><section id="sec5"><h2 class="pmc_sec_title">4. Limited Progress in High-Risk MDS and the Promise of Immune Checkpoint Inhibitors</h2>
<section id="sec6"><h3 class="pmc_sec_title">Current Standard of Care</h3>
<p>Over the past two decades, treatment strategies for high-risk myelodysplastic syndromes (HR-MDS) have remained largely unchanged, with allogeneic HSCT remaining the only potentially curative option for eligible patients.<a href="#ref-477394" class="usa-link" aria-describedby="ref-477394"><sup>30</sup></a> While HMAs such as azacitidine and decitabine are widely used, they present several limitations—including modest remission rates, unpredictable patient responses, and the requirement for multiple treatment cycles. Real-world evidence has further confirmed that HMAs are not curative, reinforcing the central role of transplant in HR-MDS management.<a href="#ref-477395" class="usa-link" aria-describedby="ref-477395"><sup>31</sup></a></p></section><section id="sec7"><h3 class="pmc_sec_title">Limitations of HMAs</h3>
<p>Despite their approval, HMAs have not substantially improved OS in HR-MDS.<a href="#ref-477396" class="usa-link" aria-describedby="ref-477396"><sup>32,33</sup></a> Combination strategies—such as HMA with lenalidomide, vorinostat, or magrolimab—have been explored, but none have yet demonstrated a survival benefit sufficient to change standard practice. One promising regimen involves venetoclax plus azacitidine, which is being evaluated as frontline therapy for HR-MDS in a single-arm phase 2 trial encompassing a broad genetic spectrum.<a href="#ref-477398" class="usa-link" aria-describedby="ref-477398"><sup>34</sup></a></p></section><section id="sec8"><h3 class="pmc_sec_title">Emerging Strategies</h3>
<p>Venetoclax combined with azacitidine is also under investigation for relapsed/refractory MDS, where it has shown encouraging rates of transfusion independence and clinical responses.<a href="#ref-477399" class="usa-link" aria-describedby="ref-477399"><sup>35</sup></a> The randomized phase 3 VERONA trial is currently underway, comparing azacitidine plus venetoclax versus azacitidine plus placebo, with complete response (CR) and OS as primary endpoints.</p>
<p>Another promising area of exploration involves targeting immune dysregulation, a hallmark of HR-MDS, that involves impaired T-cell, NK-cell, and macrophage function.<a href="#ref-477400" class="usa-link" aria-describedby="ref-477400"><sup>36</sup></a> These immunologic defects have spurred interest in immune checkpoint inhibitors (ICIs); however, the complex immunosuppressive microenvironment of HR-MDS has limited their success compared to solid tumors and other hematologic malignancies.</p>
<p>A multicenter Phase 1/1b trial of ipilimumab in relapsed hematologic malignancies HSCT demonstrated limited efficacy in HR-MDS patients.<a href="#ref-477401" class="usa-link" aria-describedby="ref-477401"><sup>37</sup></a> In another study evaluating ipilimumab in the HMA-refractory setting, marrow complete response (mCR) was achieved in one patient (3.4%), and prolonged stable disease (≥46 weeks) occurred in seven patients (24%).<a href="#ref-477402" class="usa-link" aria-describedby="ref-477402"><sup>38</sup></a> Notably, five patients were able to undergo allo-HSCT without excess toxicity. Responders exhibited higher frequencies of Inducible Co-Stimulator ( ICOS)-expressing T cells, though increased T-cell receptor diversity did not correlate with clinical outcomes. These findings suggest potential biomarkers for benefit, but underscore the limited efficacy of ipilimumab monotherapy.</p>
<p>Further randomized trials combining durvalumab with azacitidine failed to show improvement in overall response rates or progression-free survival.<a href="#ref-477403" class="usa-link" aria-describedby="ref-477403"><sup>39</sup></a> The lack of clinical activity was not attributable to altered azacitidine exposure, changes in global DNA methylation, or immune toxicity. The exact cause however remains sketchy, some hypothesis such as compensatory programmed death ligand 2 (PD-L2) upregulation or insufficient T-cell activation were proposed but not substantiated by trial data, as no significant immune activation was observed in blood or bone marrow, despite PD-1 blockade.</p>
<p>Attempts to identify responsive subpopulations, such as those with crmutations or splicing factor mutations, have also yielded disappointing results. While biologically plausible, these molecular subsets have not shown clear improvements in response to ICIs in either HR-MDS or TP53-mutant AML.<a href="#ref-477404" class="usa-link" aria-describedby="ref-477404"><sup>40,41</sup></a></p></section><section id="sec9"><h3 class="pmc_sec_title">Challenges and Future Directions</h3>
<p>Given the limitations of current therapies, alternative strategies are under exploration. One such avenue involves entinostat, a class I histone deacetylase inhibitor (HDACi), supported by preclinical findings (Tae Kon Kim, unpublished) and under clinical investigation.<a href="#ref-477406" class="usa-link" aria-describedby="ref-477406"><sup>42</sup></a> A 2014 study of vorinostat plus azacitidine demonstrated a 64% overall response rate (ORR) in a phase 1 setting.<a href="#ref-477407" class="usa-link" aria-describedby="ref-477407"><sup>43</sup></a> In a subsequent phase 2 trial enrolling HR-MDS and AML patients with poor performance status, the ORR was 30%, with 80% surviving beyond 60 days.</p>
<p>Another promising agent is oral rigosertib, which showed a 90% ORR and a 34% CR rate when combined with azacitidine in a 2019 first-line trial involving HMA-naïve HR-MDS patients.<a href="#ref-477408" class="usa-link" aria-describedby="ref-477408"><sup>44</sup></a> These results compare favorably to historical CR rates (&lt;20%) with azacitidine monotherapy. Importantly, 30% of patients achieved transfusion independence—a clinically meaningful outcome that merits further validation in a larger, randomized phase 3 trial. The regimen was also well tolerated, underscoring its potential viability in frail or elderly patient populations.</p></section></section><section id="sec10"><h2 class="pmc_sec_title">5. Future Directions in MDS: Beyond Current Limitations</h2>
<p>Despite recent therapeutic advancements, high-risk myelodysplastic syndromes (HR-MDS) remain a formidable clinical challenge with poor long-term outcomes. While HMAs remain the standard of care, they confer only modest survival benefits, and resistance is common, often culminating in disease progression. Allogeneic HSCT remains the only potentially curative option for patients with HR-MDS.<a href="#ref-477409" class="usa-link" aria-describedby="ref-477409"><sup>45</sup></a></p>
<p>Given these limitations, novel biologic agents are being actively investigated to target critical pathways involved in MDS pathogenesis.</p>
<section id="sec11"><h3 class="pmc_sec_title">Immunotherapies and Targeted Agents</h3>
<p>Sabatolimab, a humanized monoclonal antibody against T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)—a key regulator of immune responses and leukemia progression—has emerged as a promising immunotherapeutic candidate.<a href="#ref-477410" class="usa-link" aria-describedby="ref-477410"><sup>46</sup></a> In the STIMULUS-MDS1 phase II trial, sabatolimab combined with HMA demonstrated an acceptable safety profile in patients with intermediate to very high-risk MDS, but failed to significantly improve CR rates or PFS.<a href="#ref-477411" class="usa-link" aria-describedby="ref-477411"><sup>47,48</sup></a> Despite this, the favourable safety data supported its advancement to the STIMULUS-MDS2 phase III trial, which included patients with CMML to assess its effect on OS.<a href="#ref-477413" class="usa-link" aria-describedby="ref-477413"><sup>49</sup></a> However, the trial was suspended in January 2024 due to failure to meet its primary endpoint. TIM-3 co-expression with PD-1 and LAG-3 and the ‘cold’ MDS marrow microenvironment may limit monotherapy efficacy in the absence of predictive biomarkers.<a href="#ref-477440" class="usa-link" aria-describedby="ref-477440"><sup>50,51</sup></a></p>
<p>Pevonedistat, a selective inhibitor of the Neural Precursor Cell Expressed Developmentally Downgraded 8 (NEDD8-activating enzyme) critical for ubiquitination and protein degradation, initially demonstrated promise when combined with azacitidine, improving overall survival (OS), event-free survival (EFS), and response duration in early-phase studies.<a href="#ref-477414" class="usa-link" aria-describedby="ref-477414"><sup>52–54</sup></a> However, the phase III PANTHER trial failed to show a significant difference in median EFS or OS, contrasting earlier findings.<a href="#ref-477417" class="usa-link" aria-describedby="ref-477417"><sup>55</sup></a> Pevonedistat’s cytostatic rather than cytotoxic mechanism and non-selective hematopoietic suppression, combined with a lack of biomarker-driven selection during trials, likely contributed to its limited clinical efficacy.<a href="#ref-477442" class="usa-link" aria-describedby="ref-477442"><sup>56</sup></a></p>
<p>Eprenetapopt, a first-in-class small molecule that restores wild-type p53 function in TP53-mutant cells, has shown encouraging results in early trials.<a href="#ref-477418" class="usa-link" aria-describedby="ref-477418"><sup>57,58</sup></a> A phase Ib/II study combining eprenetapopt with azacitidine reported promising CR rates in TP53-mutant MDS. Nevertheless, febrile neutropenia occurred in one-third of patients, raising safety concerns despite the agent’s efficacy.<a href="#ref-477419" class="usa-link" aria-describedby="ref-477419"><sup>58</sup></a> APR-246’s p53-independent oxidative stress and unstratified TP53 mutational heterogeneity likely contributed to the off-target toxicity and variable responses.<a href="#ref-477443" class="usa-link" aria-describedby="ref-477443"><sup>59</sup></a></p></section><section id="sec12"><h3 class="pmc_sec_title">Therapies with Limited Clinical Impact</h3>
<p>Several agents that showed early promise failed to demonstrate clinical benefit in later trials. Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, combined with low-dose cytarabine, achieved only a 20% response rate and was associated with a high discontinuation rate due to toxicity.<a href="#ref-477420" class="usa-link" aria-describedby="ref-477420"><sup>60</sup></a> Glasdegib’s limited efficacy may reflect pathway cross-talk with SDF-1/CXCR4 signaling and absence of predictive baseline mutations, highlighting the need for biomarker-driven strategies targeting LSC-associated resistance mechanisms.<a href="#ref-477444" class="usa-link" aria-describedby="ref-477444"><sup>61</sup></a> Rigosertib, a renin-angiotensin system (RAS) pathway inhibitor, failed to improve OS in a phase III trial,<a href="#ref-477421" class="usa-link" aria-describedby="ref-477421"><sup>62</sup></a> although a more recent phase I/II study combining it with azacitidine showed improved ORR, suggesting potential synergy that warrants further investigation.<a href="#ref-477422" class="usa-link" aria-describedby="ref-477422"><sup>63</sup></a> Rigosertib likely failed due to an unclear mechanism and lack of biomarker-based selection (marrow blast percentage), despite early signs of synergy with azacitidine.<a href="#ref-477445" class="usa-link" aria-describedby="ref-477445"><sup>64</sup></a> Magrolimab, a CD47-targeting monoclonal antibody, demonstrated an impressive 75% ORR and 33% CR rate when combined with azacitidine in TP53-mutated MDS,<a href="#ref-477423" class="usa-link" aria-describedby="ref-477423"><sup>65</sup></a> but the phase III ENHANCE trial was ultimately discontinued due to futility.<a href="#ref-477424" class="usa-link" aria-describedby="ref-477424"><sup>66</sup></a> CD47’s expression on erythrocytes led to anemia and hemolytic toxicity, while TAM-driven immunosuppression and adaptive resistance likely limited magrolimab’s long-term efficacy in MDS.<a href="#ref-477446" class="usa-link" aria-describedby="ref-477446"><sup>67</sup></a></p>
<p>Tamibarotene (SY-1425), a selective retinoic acid receptor alpha (RARα) agonist, demonstrated improved clinical outcomes in RARα-positive HR-MDS when combined with azacitidine in early trials.<a href="#ref-477425" class="usa-link" aria-describedby="ref-477425"><sup>68,69</sup></a> However, the SELECT-MDS-1 phase III trial was discontinued in November 2024 after failing to meet its primary endpoint.<a href="#ref-477427" class="usa-link" aria-describedby="ref-477427"><sup>70</sup></a> Tamibarotene likely failed due to variable or transient RARα expression and limited patient stratification, undermining its efficacy in an unselected HR-MDS population.<a href="#ref-477447" class="usa-link" aria-describedby="ref-477447"><sup>71</sup></a></p>
<p>These failures highlight the need for mechanism-aligned trial design—matching to oncogenic drivers or immune escape pathways, integrating molecular stratification (e.g., TIM-3⁺, TP53 multi-hit), and incorporating dynamic pharmacodynamic biomarkers.</p></section><section id="sec13"><h3 class="pmc_sec_title">Immune Checkpoint Inhibitors</h3>
<p>Checkpoint inhibitors have also been evaluated in MDS. PD-1 inhibitors, such as pembrolizumab and nivolumab, showed some efficacy in newly diagnosed HR-MDS, but their benefit was limited in HMA-refractory settings.<a href="#ref-477428" class="usa-link" aria-describedby="ref-477428"><sup>72–74</sup></a> PD-L1 inhibition with durvalumab resulted in improved ORR but was constrained by notable toxicity.<a href="#ref-477431" class="usa-link" aria-describedby="ref-477431"><sup>75</sup></a> These findings suggest that combination strategies may be required to fully realize the potential of checkpoint blockade in HR-MDS.</p>
<p>CTLA-4 blockade with ipilimumab demonstrated a 21% clinical benefit rate in a phase Ib trial for HMA-refractory HR-MDS.<a href="#ref-477432" class="usa-link" aria-describedby="ref-477432"><sup>76,77</sup></a> A subsequent phase II study combining ipilimumab with azacitidine achieved an ORR of 71% (compared to 35% with ipilimumab alone), supporting further evaluation in larger studies.<a href="#ref-477434" class="usa-link" aria-describedby="ref-477434"><sup>78</sup></a></p></section><section id="sec14"><h3 class="pmc_sec_title">Emerging Therapeutic Strategies</h3>
<p>While numerous agents have failed to achieve their primary endpoints in late-phase trials, ongoing efforts are exploring innovative therapeutic modalities, including kinase inhibitors, immune-based strategies, and adoptive cell therapies aimed at overcoming resistance and improving outcomes.</p>
<p>Bemcentinib, a selective AXL receptor tyrosine kinase inhibitor, was evaluated in the BERMAGO phase II trial for refractory HR-MDS. Despite a favorable safety profile, limited clinical efficacy led to early termination due to disease progression (<a href="https://clinicaltrials.gov/ct2/show/NCT03824080" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03824080</a>).<a href="#ref-477435" class="usa-link" aria-describedby="ref-477435"><sup>79</sup></a> Emavusertib, an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor involved in Toll-like receptor and interleukin-1 receptor (IL-1R) signaling, is under evaluation in combination with venetoclax for HR-MDS and AML (NCT0427876800). Tomaralimab, a monoclonal antibody targeting Toll likereceptor 2 (TLR2), overexpressed in CD34+ cells in low-risk MDS, has shown potential for patients with HMA-refractory LR-MDS.<a href="#ref-477436" class="usa-link" aria-describedby="ref-477436"><sup>80</sup></a></p></section><section id="sec15"><h3 class="pmc_sec_title">Adoptive Cell Therapies</h3>
<p>Adoptive T-cell therapies, including chimeric antigen receptor T-cell therapy (CAR-T), tumor infiltrating lymphocytes (TIL), and T-cell receptor T-cell therapy (TCR-T), have revolutionized lymphoma treatment, but remain underexplored in myeloid malignancies. CAR-T therapies targeting NKG2D (<a href="https://clinicaltrials.gov/ct2/show/NCT02203825" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02203825</a>) and CD123 show early promise in HR-MDS.<a href="#ref-477433" class="usa-link" aria-describedby="ref-477433"><sup>77</sup></a></p>
<p>Dendritic cell (DC)-based immunotherapies, such as MoDC and DCleu vaccines, enhance antigen presentation and leukemia-specific T-cell responses, offering potential therapeutic benefit in HR-MDS.<a href="#ref-477437" class="usa-link" aria-describedby="ref-477437"><sup>81,82</sup></a></p>
<p>Similarly, natural killer (NK) cell adoptive transfer has shown anti-tumor activity in HR-MDS. Preclinical and early <em>in vivo</em> studies suggest NK cell infusion may serve as a bridge to allogeneic HSCT, though further investigation is required to optimize combinations and improve efficacy.<a href="#ref-477439" class="usa-link" aria-describedby="ref-477439"><sup>83</sup></a></p>
<p>While significant obstacles remain in HR-MDS treatment, ongoing development of targeted agents, immunotherapies, and cellular strategies continues to offer hope for transformative therapies and improved patient outcomes.</p></section></section><section id="sec16"><h2 class="pmc_sec_title">Conclusion</h2>
<p>The therapeutic landscape of MDS has evolved significantly over the past decade, yet major challenges persist, particularly in the treatment of HR-MDS with poor prognoses and limited responses to current therapies. While hypomethylating agents remain the cornerstone of treatment, their transient efficacy highlights the need for more effective and personalized approaches.</p>
<p>The emergence of novel agents including luspatercept and imetelstat have redefined care in lower-risk MDS, while promising novel strategies—including p53 reactivators, CD47 inhibitors, T-cell TIM-3 blockers, and immune checkpoint inhibitors—are reshaping the treatment paradigm in higher-risk disease. Despite early successes, many investigational agents have failed to demonstrate sustained clinical benefit in late-phase trials, underscoring the complexity of MDS pathogenesis and resistance mechanisms. However, the emergence of advanced molecular profiling, risk-adapted treatment strategies, and combination approaches has laid the foundation for a more precise and dynamic therapeutic framework.</p>
<p>A major limitation in the current treatment approach lies in the clinical trial design, where molecular heterogeneity is often overlooked. Many studies continue to apply the same treatment models to biologically diverse patient populations, limiting the potential to identify effective personalized therapies. Moreover, the absence of dynamic tools such as MRD monitoring prevents timely treatment adaptation and prediction of possible relapses.</p>
<p>As our understanding of the genetic, immunologic, and microenvironmental drivers of MDS continues to deepen, the integration of novel agents—combined with predictive biomarkers and innovative trial designs—will be critical in advancing personalized care. Future research must focus on real-time molecular testing to guide therapy tailored to patients’ individual risk, and rational combination therapies that target both the primary disease drivers and the tumor microenvironment. Importance must be given to the development of adaptive clinical trial designs, exploring early intervention strategies in patients with clonal cytopenias, and emphasizing on quality of life outcomes alongside survival metrics.</p>
<p>Ultimately, while challenges remain, the convergence of translational science, clinical innovation and patient-centered research offers renewed hope for achieving durable remissions and improved long-term outcomes in patients with MDS.</p>
<section id="contrib"><h3 class="pmc_sec_title">Author Contributions (CRediT Taxonomy)</h3>
<p>Conceptualization: Viviana Cortiana, Harshitha Vallabhaneni, Yan Leyfman</p>
<p>Methodology: Viviana Cortiana, Harshitha Vallabhaneni, Kennedy Itodo</p>
<p>Formal Analysis: Jenna Ghazal, Taha Kassim Dohadwala</p>
<p>Investigation: Viviana Cortiana, Harshitha Vallabhaneni, Jenna Ghazal</p>
<p>Writing – Original Draft Preparation: Viviana Cortiana, Harshitha Vallabhaneni, Jenna Ghazal</p>
<p>Writing – Review &amp; Editing: Yan Leyfman, Chandler H. Park, Kennedy Itodo</p>
<p>Resources: Yan Leyfman, Chandler H. Park</p>
<p>Supervision: Yan Leyfman, Chandler H. Park</p>
<p>Visualization: Jenna Ghazal, Taha Kassim Dohadwala, Harshitha Vallabhaneni</p>
<p>Project Administration: Viviana Cortiana</p></section><section id="sec18"><h3 class="pmc_sec_title">Institutional Review Board Statement</h3>
<p>Not applicable.</p></section><section id="sec19"><h3 class="pmc_sec_title">Informed Consent Statement</h3>
<p>Not applicable.</p></section><section id="coi"><h3 class="pmc_sec_title">Conflicts of Interest</h3>
<p>The authors declare no conflicts of interest.</p></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<section id="ack"><h3 class="pmc_sec_title">Acknowledgments</h3>
<p>We thank Amer Zeidan for the opportunity to learn from a global Leader in Medicine.</p></section></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This research received no external funding.</p></section><section id="data"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>No patient data was directly utilized in this study.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="ref-477375">
<span class="label">1.</span><cite>Zeidan A. Immune checkpoint inhibition and novel therapies for myelodysplastic syndromes/neoplasms; Online. </cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Immune%20checkpoint%20inhibition%20and%20novel%20therapies%20for%20myelodysplastic%20syndromes/neoplasms&amp;author=A.%20Zeidan&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477376">
<span class="label">2.</span><cite>Management of the older patient with myelodysplastic syndrome. Shallis R. M., Zeidan A. M. 2021Drugs Aging. 38(9):751–767. doi: 10.1007/s40266-021-00881-3. <a href="https://doi.org/10.1007/s40266-021-00881-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1007/s40266-021-00881-3</a></cite> [<a href="https://doi.org/10.1007/s40266-021-00881-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34342860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs%20Aging&amp;title=Management%20of%20the%20older%20patient%20with%20myelodysplastic%20syndrome&amp;author=R.%20M.%20Shallis&amp;author=A.%20M.%20Zeidan&amp;volume=38&amp;issue=9&amp;pages=751-767&amp;pmid=34342860&amp;doi=10.1007/s40266-021-00881-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477377">
<span class="label">3.</span><cite>How I diagnose low-grade myelodysplastic syndromes. Siddon A. J., Hasserjian R. P. 2020Am J Clin Pathol. 154(1):5–14. doi: 10.1093/ajcp/aqaa046. <a href="https://doi.org/10.1093/ajcp/aqaa046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/ajcp/aqaa046</a></cite> [<a href="https://doi.org/10.1093/ajcp/aqaa046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32458977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Clin%20Pathol&amp;title=How%20I%20diagnose%20low-grade%20myelodysplastic%20syndromes&amp;author=A.%20J.%20Siddon&amp;author=R.%20P.%20Hasserjian&amp;volume=154&amp;issue=1&amp;pages=5-14&amp;pmid=32458977&amp;doi=10.1093/ajcp/aqaa046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477378">
<span class="label">4.</span><cite>Myelodysplastic Syndromes Risk Factors | American Cancer Society.  [2025-6-19]. <a href="https://www.cancer.org/cancer/types/myelodysplastic-syndrome/causes-risks-prevention/risk-factors.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.cancer.org/cancer/types/myelodysplastic-syndrome/causes-risks-prevention/risk-factors.html</a></cite>
</li>
<li id="ref-477379">
<span class="label">5.</span><cite>CHIPing away the progression potential of CHIP: A new reality in the making. Xie Z., Zeidan A. M. 2023Blood Rev. 58:101001. doi: 10.1016/j.blre.2022.101001. <a href="https://doi.org/10.1016/j.blre.2022.101001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.blre.2022.101001</a></cite> [<a href="https://doi.org/10.1016/j.blre.2022.101001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35989137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Rev&amp;title=CHIPing%20away%20the%20progression%20potential%20of%20CHIP:%20A%20new%20reality%20in%20the%20making&amp;author=Z.%20Xie&amp;author=A.%20M.%20Zeidan&amp;volume=58&amp;pages=101001&amp;pmid=35989137&amp;doi=10.1016/j.blre.2022.101001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477380">
<span class="label">6.</span><cite>Clinical significance of somatic mutation in unexplained blood cytopenia. Malcovati L., Gallì A., Travaglino E.., et al.  2017Blood. 129(25):3371–3378. doi: 10.1182/blood-2017-01-763425. <a href="https://doi.org/10.1182/blood-2017-01-763425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2017-01-763425</a></cite> [<a href="https://doi.org/10.1182/blood-2017-01-763425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5542849/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28424163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Clinical%20significance%20of%20somatic%20mutation%20in%20unexplained%20blood%20cytopenia&amp;author=L.%20Malcovati&amp;author=A.%20Gall%C3%AC&amp;author=E..%20Travaglino&amp;volume=129&amp;issue=25&amp;pages=3371-3378&amp;pmid=28424163&amp;doi=10.1182/blood-2017-01-763425&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477381">
<span class="label">7.</span><cite>Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Cargo C. A., Rowbotham N., Evans P. A.., et al.  2015Blood. 126(21):2362–2365. doi: 10.1182/blood-2015-08-663237. <a href="https://doi.org/10.1182/blood-2015-08-663237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2015-08-663237</a></cite> [<a href="https://doi.org/10.1182/blood-2015-08-663237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26392596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Targeted%20sequencing%20identifies%20patients%20with%20preclinical%20MDS%20at%20high%20risk%20of%20disease%20progression&amp;author=C.%20A.%20Cargo&amp;author=N.%20Rowbotham&amp;author=P.%20A..%20Evans&amp;volume=126&amp;issue=21&amp;pages=2362-2365&amp;pmid=26392596&amp;doi=10.1182/blood-2015-08-663237&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477382">
<span class="label">8.</span><cite>The genetic landscape of myelodysplastic neoplasm progression to acute myeloid leukemia. Bănescu C., Tripon F., Muntean C. Mar 17;2023 Int J Mol Sci. 24(6):5734. doi: 10.3390/ijms24065734. <a href="https://doi.org/10.3390/ijms24065734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3390/ijms24065734</a></cite> [<a href="https://doi.org/10.3390/ijms24065734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10058431/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36982819/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=The%20genetic%20landscape%20of%20myelodysplastic%20neoplasm%20progression%20to%20acute%20myeloid%20leukemia&amp;author=C.%20B%C4%83nescu&amp;author=F.%20Tripon&amp;author=C.%20Muntean&amp;volume=24&amp;issue=6&amp;pages=5734&amp;pmid=36982819&amp;doi=10.3390/ijms24065734&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477383">
<span class="label">9.</span><cite>Comparison of the 2022 World Health Organization classification and International Consensus Classification in myelodysplastic syndromes/neoplasms. Lee W. H., Lin C. C., Tsai C. H.., et al.  Apr 9;2024 Blood Cancer J. 14(1):57. doi: 10.1038/s41408-024-01031-9. <a href="https://doi.org/10.1038/s41408-024-01031-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41408-024-01031-9</a></cite> [<a href="https://doi.org/10.1038/s41408-024-01031-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11004131/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38594285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&amp;title=Comparison%20of%20the%202022%20World%20Health%20Organization%20classification%20and%20International%20Consensus%20Classification%20in%20myelodysplastic%20syndromes/neoplasms&amp;author=W.%20H.%20Lee&amp;author=C.%20C.%20Lin&amp;author=C.%20H..%20Tsai&amp;volume=14&amp;issue=1&amp;pages=57&amp;pmid=38594285&amp;doi=10.1038/s41408-024-01031-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477384">
<span class="label">10.</span><cite>The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification. Nachtkamp K., Strupp C., Vukelja M.., et al.  2024Leukemia. 38(2):442–445. doi: 10.1038/s41375-024-02157-2. <a href="https://doi.org/10.1038/s41375-024-02157-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41375-024-02157-2</a></cite> [<a href="https://doi.org/10.1038/s41375-024-02157-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10844089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38263435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=The%20new%20WHO%202022%20and%20ICC%20proposals%20for%20the%20classification%20of%20myelodysplastic%20neoplasms.%20Validation%20based%20on%20the%20D%C3%BCsseldorf%20MDS%20Registry%20and%20proposals%20for%20a%20merged%20classification&amp;author=K.%20Nachtkamp&amp;author=C.%20Strupp&amp;author=M..%20Vukelja&amp;volume=38&amp;issue=2&amp;pages=442-445&amp;pmid=38263435&amp;doi=10.1038/s41375-024-02157-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477385">
<span class="label">11.</span><cite>The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: An analysis of 3307 cases. Stengel A., Kern W., Haferlach T.., et al.  2017Leukemia. 31(3):705–711. doi: 10.1038/leu.2016.263. <a href="https://doi.org/10.1038/leu.2016.263" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/leu.2016.263</a></cite> [<a href="https://doi.org/10.1038/leu.2016.263" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27680515/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=The%20impact%20of%20TP53%20mutations%20and%20TP53%20deletions%20on%20survival%20varies%20between%20AML,%20ALL,%20MDS%20and%20CLL:%20An%20analysis%20of%203307%20cases&amp;author=A.%20Stengel&amp;author=W.%20Kern&amp;author=T..%20Haferlach&amp;volume=31&amp;issue=3&amp;pages=705-711&amp;pmid=27680515&amp;doi=10.1038/leu.2016.263&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477386">
<span class="label">12.</span><cite>Therapeutic outcomes and prognostic impact of gene mutations including TP53 and SF3B1 in patients with del(5q) myelodysplastic syndromes (MDS) Chan O., Ali N. A., Sallman D.., et al.  2022Clin Lymphoma Myeloma Leuk. 22(7):e467–e476. doi: 10.1016/j.clml.2022.01.002. <a href="https://doi.org/10.1016/j.clml.2022.01.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.clml.2022.01.002</a></cite> [<a href="https://doi.org/10.1016/j.clml.2022.01.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35101379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lymphoma%20Myeloma%20Leuk&amp;title=Therapeutic%20outcomes%20and%20prognostic%20impact%20of%20gene%20mutations%20including%20TP53%20and%20SF3B1%20in%20patients%20with%20del(5q)%20myelodysplastic%20syndromes%20(MDS)&amp;author=O.%20Chan&amp;author=N.%20A.%20Ali&amp;author=D..%20Sallman&amp;volume=22&amp;issue=7&amp;pages=e467-e476&amp;pmid=35101379&amp;doi=10.1016/j.clml.2022.01.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477387">
<span class="label">13.</span><cite>Review of the response criteria for myelodysplastic syndrome. Conley A. P., Stevenson W., Garcia-Manero G. 2007Eur Oncol Haematol. 30 doi: 10.17925/EOH.2007.0.0.30. <a href="https://doi.org/10.17925/EOH.2007.0.0.30" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.17925/EOH.2007.0.0.30</a></cite> [<a href="https://doi.org/10.17925/EOH.2007.0.0.30" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Oncol%20Haematol&amp;title=Review%20of%20the%20response%20criteria%20for%20myelodysplastic%20syndrome&amp;author=A.%20P.%20Conley&amp;author=W.%20Stevenson&amp;author=G.%20Garcia-Manero&amp;volume=30&amp;doi=10.17925/EOH.2007.0.0.30&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477388">
<span class="label">14.</span><cite>Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Cheson B. D., Greenberg P. L., Bennett J. M.., et al.  2006Blood. 108(2):419–425. doi: 10.1182/blood-2005-10-4149. <a href="https://doi.org/10.1182/blood-2005-10-4149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2005-10-4149</a></cite> [<a href="https://doi.org/10.1182/blood-2005-10-4149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16609072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Clinical%20application%20and%20proposal%20for%20modification%20of%20the%20International%20Working%20Group%20(IWG)%20response%20criteria%20in%20myelodysplasia&amp;author=B.%20D.%20Cheson&amp;author=P.%20L.%20Greenberg&amp;author=J.%20M..%20Bennett&amp;volume=108&amp;issue=2&amp;pages=419-425&amp;pmid=16609072&amp;doi=10.1182/blood-2005-10-4149&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477389">
<span class="label">15.</span><cite>An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Savona M. R., Malcovati L., Komrokji R.., et al.  2015Blood. 125(12):1857–1865. doi: 10.1182/blood-2014-10-607341. <a href="https://doi.org/10.1182/blood-2014-10-607341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2014-10-607341</a></cite> [<a href="https://doi.org/10.1182/blood-2014-10-607341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4915792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25624319/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=An%20international%20consortium%20proposal%20of%20uniform%20response%20criteria%20for%20myelodysplastic/myeloproliferative%20neoplasms%20(MDS/MPN)%20in%20adults&amp;author=M.%20R.%20Savona&amp;author=L.%20Malcovati&amp;author=R..%20Komrokji&amp;volume=125&amp;issue=12&amp;pages=1857-1865&amp;pmid=25624319&amp;doi=10.1182/blood-2014-10-607341&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477390">
<span class="label">16.</span><cite>Evolution of therapeutic benefit measurement criteria in myelodysplastic syndromes/neoplasms. Stempel J. M., Xie Z., Bewersdorf J. P.., et al.  2023Cancer J. 29(3):203–211. doi: 10.1097/PPO.0000000000000666. <a href="https://doi.org/10.1097/PPO.0000000000000666" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1097/PPO.0000000000000666</a></cite> [<a href="https://doi.org/10.1097/PPO.0000000000000666" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37195777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20J&amp;title=Evolution%20of%20therapeutic%20benefit%20measurement%20criteria%20in%20myelodysplastic%20syndromes/neoplasms&amp;author=J.%20M.%20Stempel&amp;author=Z.%20Xie&amp;author=J.%20P..%20Bewersdorf&amp;volume=29&amp;issue=3&amp;pages=203-211&amp;pmid=37195777&amp;doi=10.1097/PPO.0000000000000666&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477448">
<span class="label">17.</span><cite>Implications of TP53 Allelic State for Genome Stability, Clinical Presentation, and Outcomes in Myelodysplastic Syndromes. Bernard E., Nannya Y., Hasserjian R. P.., et al.  2020Nat Med. 26(10):1549–1556. doi: 10.1038/s41591-020-1008-z. <a href="https://doi.org/10.1038/s41591-020-1008-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41591-020-1008-z</a></cite> [<a href="https://doi.org/10.1038/s41591-020-1008-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8381722/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32747829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Implications%20of%20TP53%20Allelic%20State%20for%20Genome%20Stability,%20Clinical%20Presentation,%20and%20Outcomes%20in%20Myelodysplastic%20Syndromes&amp;author=E.%20Bernard&amp;author=Y.%20Nannya&amp;author=R.%20P..%20Hasserjian&amp;volume=26&amp;issue=10&amp;pages=1549-1556&amp;pmid=32747829&amp;doi=10.1038/s41591-020-1008-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477449">
<span class="label">18.</span><cite>Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Sallman D. A., DeZern A. E., Garcia-Manero G.., et al.  2021J Clin Oncol. 39(14):1584–1594. doi: 10.1200/JCO.20.01978. <a href="https://doi.org/10.1200/JCO.20.01978" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1200/JCO.20.01978</a></cite> [<a href="https://doi.org/10.1200/JCO.20.01978" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8099410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33449813/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Eprenetapopt%20(APR-246)%20and%20Azacitidine%20in%20TP53-Mutant%20Myelodysplastic%20Syndromes&amp;author=D.%20A.%20Sallman&amp;author=A.%20E.%20DeZern&amp;author=G..%20Garcia-Manero&amp;volume=39&amp;issue=14&amp;pages=1584-1594&amp;pmid=33449813&amp;doi=10.1200/JCO.20.01978&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477450">
<span class="label">19.</span><cite>Current Challenges and Unmet Medical Needs in Myelodysplastic Syndromes. Platzbecker U., Kubasch A. S., Homer-Bouthiette C., Prebet T. 2021Leukemia. 35(8):2182–2198. doi: 10.1038/s41375-021-01236-3. <a href="https://doi.org/10.1038/s41375-021-01236-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41375-021-01236-3</a></cite> [<a href="https://doi.org/10.1038/s41375-021-01236-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8324480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34045662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Current%20Challenges%20and%20Unmet%20Medical%20Needs%20in%20Myelodysplastic%20Syndromes&amp;author=U.%20Platzbecker&amp;author=A.%20S.%20Kubasch&amp;author=C.%20Homer-Bouthiette&amp;author=T.%20Prebet&amp;volume=35&amp;issue=8&amp;pages=2182-2198&amp;pmid=34045662&amp;doi=10.1038/s41375-021-01236-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477451">
<span class="label">20.</span><cite>Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts. Papaemmanuil E., Cazzola M., Boultwood J.., et al.  2011N Engl J Med. 365(15):1384–1395. doi: 10.1056/NEJMoa1103283. <a href="https://doi.org/10.1056/NEJMoa1103283" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1056/NEJMoa1103283</a></cite> [<a href="https://doi.org/10.1056/NEJMoa1103283" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3322589/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21995386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Somatic%20SF3B1%20Mutation%20in%20Myelodysplasia%20with%20Ring%20Sideroblasts&amp;author=E.%20Papaemmanuil&amp;author=M.%20Cazzola&amp;author=J..%20Boultwood&amp;volume=365&amp;issue=15&amp;pages=1384-1395&amp;pmid=21995386&amp;doi=10.1056/NEJMoa1103283&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477453">
<span class="label">21.</span><cite>Luspatercept for Anemia in Patients with Lower-Risk Myelodysplastic Syndromes. Komrokji R. S., Garcia-Manero G., Ades L.., et al.  2021Haematologica. 106(12):3184–3187. doi: 10.3324/haematol.2021.279235. <a href="https://doi.org/10.3324/haematol.2021.279235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3324/haematol.2021.279235</a></cite> [<a href="https://doi.org/10.3324/haematol.2021.279235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Luspatercept%20for%20Anemia%20in%20Patients%20with%20Lower-Risk%20Myelodysplastic%20Syndromes&amp;author=R.%20S.%20Komrokji&amp;author=G.%20Garcia-Manero&amp;author=L..%20Ades&amp;volume=106&amp;issue=12&amp;pages=3184-3187&amp;doi=10.3324/haematol.2021.279235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477454">
<span class="label">22.</span><cite>The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Khoury J. D., Solary E., Abla O.., et al.  2022Leukemia. 36(7):1703–1719. doi: 10.1038/s41375-022-01520-1. <a href="https://doi.org/10.1038/s41375-022-01520-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41375-022-01520-1</a></cite> [<a href="https://doi.org/10.1038/s41375-022-01520-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9252913/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35732831/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=The%205th%20Edition%20of%20the%20World%20Health%20Organization%20Classification%20of%20Haematolymphoid%20Tumours:%20Myeloid%20and%20Histiocytic/Dendritic%20Neoplasms&amp;author=J.%20D.%20Khoury&amp;author=E.%20Solary&amp;author=O..%20Abla&amp;volume=36&amp;issue=7&amp;pages=1703-1719&amp;pmid=35732831&amp;doi=10.1038/s41375-022-01520-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477452">
<span class="label">23.</span><cite>Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. Fenaux P., Platzbecker U., Mufti G. J.., et al.  2020N Engl J Med. 382(2):140–151. doi: 10.1056/NEJMoa1908892. <a href="https://doi.org/10.1056/NEJMoa1908892" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1056/NEJMoa1908892</a></cite> [<a href="https://doi.org/10.1056/NEJMoa1908892" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31914241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Luspatercept%20in%20Patients%20with%20Lower-Risk%20Myelodysplastic%20Syndromes&amp;author=P.%20Fenaux&amp;author=U.%20Platzbecker&amp;author=G.%20J..%20Mufti&amp;volume=382&amp;issue=2&amp;pages=140-151&amp;pmid=31914241&amp;doi=10.1056/NEJMoa1908892&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477455">
<span class="label">24.</span><cite>Prognostic Value of TET2 Mutations in Low-Risk Myelodysplastic Syndromes. Itzykson R., Kosmider O., Renneville A.., et al.  2011Blood. 118(14):3795–3801. doi: 10.1182/blood-2011-03-341784. <a href="https://doi.org/10.1182/blood-2011-03-341784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2011-03-341784</a></cite> [<a href="https://doi.org/10.1182/blood-2011-03-341784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Prognostic%20Value%20of%20TET2%20Mutations%20in%20Low-Risk%20Myelodysplastic%20Syndromes&amp;author=R.%20Itzykson&amp;author=O.%20Kosmider&amp;author=A..%20Renneville&amp;volume=118&amp;issue=14&amp;pages=3795-3801&amp;doi=10.1182/blood-2011-03-341784&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477456">
<span class="label">25.</span><cite>Landscape of Genetic Lesions in 944 Patients with Myelodysplastic Syndromes. Haferlach T., Nagata Y., Grossmann V.., et al.  2014Leukemia. 28(2):241–247. doi: 10.1038/leu.2013.336. <a href="https://doi.org/10.1038/leu.2013.336" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/leu.2013.336</a></cite> [<a href="https://doi.org/10.1038/leu.2013.336" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3918868/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24220272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Landscape%20of%20Genetic%20Lesions%20in%20944%20Patients%20with%20Myelodysplastic%20Syndromes&amp;author=T.%20Haferlach&amp;author=Y.%20Nagata&amp;author=V..%20Grossmann&amp;volume=28&amp;issue=2&amp;pages=241-247&amp;pmid=24220272&amp;doi=10.1038/leu.2013.336&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477457">
<span class="label">26.</span><cite>Frequency and Prognostic Impact of Mutations in SRSF2, U2AF1, and ZRSR2 in Patients with Myelodysplastic Syndromes. Thol F., Kade S., Schlarmann C.., et al.  2012Blood. 119(15):3578–3584. doi: 10.1182/blood-2011-12-399345. <a href="https://doi.org/10.1182/blood-2011-12-399345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2011-12-399345</a></cite> [<a href="https://doi.org/10.1182/blood-2011-12-399345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22389253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Frequency%20and%20Prognostic%20Impact%20of%20Mutations%20in%20SRSF2,%20U2AF1,%20and%20ZRSR2%20in%20Patients%20with%20Myelodysplastic%20Syndromes&amp;author=F.%20Thol&amp;author=S.%20Kade&amp;author=C..%20Schlarmann&amp;volume=119&amp;issue=15&amp;pages=3578-3584&amp;pmid=22389253&amp;doi=10.1182/blood-2011-12-399345&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477391">
<span class="label">27.</span><cite>Luspatercept in patients with lower-risk myelodysplastic syndromes. Fenaux P., Platzbecker U., Mufti G. J.., et al.  2020N Engl J Med. 382(2):140–151. doi: 10.1056/NEJMoa1908892. <a href="https://doi.org/10.1056/NEJMoa1908892" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1056/NEJMoa1908892</a></cite> [<a href="https://doi.org/10.1056/NEJMoa1908892" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31914241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Luspatercept%20in%20patients%20with%20lower-risk%20myelodysplastic%20syndromes&amp;author=P.%20Fenaux&amp;author=U.%20Platzbecker&amp;author=G.%20J..%20Mufti&amp;volume=382&amp;issue=2&amp;pages=140-151&amp;pmid=31914241&amp;doi=10.1056/NEJMoa1908892&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477392">
<span class="label">28.</span><cite>The COMMANDS Trial: A phase 3 study of the efficacy and safety of luspatercept versus epoetin alfa for the treatment of anemia due to IPSS-R very low-, low-, or intermediate-risk MDS in erythropoiesis stimulating agent-naive patients who require RBC transfusions. Della Porta M., Platzbecker U., Santini V.., et al.  2020Blood. 136(suppl 1):1–2. doi: 10.1182/blood-2020-140284. <a href="https://doi.org/10.1182/blood-2020-140284" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2020-140284</a></cite> [<a href="https://doi.org/10.1182/blood-2020-140284" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20COMMANDS%20Trial:%20A%20phase%203%20study%20of%20the%20efficacy%20and%20safety%20of%20luspatercept%20versus%20epoetin%20alfa%20for%20the%20treatment%20of%20anemia%20due%20to%20IPSS-R%20very%20low-,%20low-,%20or%20intermediate-risk%20MDS%20in%20erythropoiesis%20stimulating%20agent-naive%20patients%20who%20require%20RBC%20transfusions&amp;author=M.%20Della%20Porta&amp;author=U.%20Platzbecker&amp;author=V..%20Santini&amp;volume=136&amp;issue=suppl%201&amp;pages=1-2&amp;doi=10.1182/blood-2020-140284&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477393">
<span class="label">29.</span><cite>IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA) Zeidan A. M., Platzbecker U., Santini V.., et al.  2023J Clin Oncol. 41(16 suppl):7004–7004. doi: 10.1200/jco.2023.41.16_suppl.7004. <a href="https://doi.org/10.1200/jco.2023.41.16_suppl.7004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1200/jco.2023.41.16_suppl.7004</a></cite> [<a href="https://doi.org/10.1200/jco.2023.41.16_suppl.7004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=IMerge:%20Results%20from%20a%20phase%203,%20randomized,%20double-blind,%20placebo-controlled%20study%20of%20imetelstat%20in%20patients%20(pts)%20with%20heavily%20transfusion%20dependent%20(TD)%20non-del(5q)%20lower-risk%20myelodysplastic%20syndromes%20(LR-MDS)%20relapsed/refractory%20(R/R)%20to%20erythropoiesis%20stimulating%20agents%20(ESA)&amp;author=A.%20M.%20Zeidan&amp;author=U.%20Platzbecker&amp;author=V..%20Santini&amp;volume=41&amp;issue=16%20suppl&amp;pages=7004-7004&amp;doi=10.1200/jco.2023.41.16_suppl.7004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477394">
<span class="label">30.</span><cite>Novel approaches and future directions in myelodysplastic syndrome treatment. Bewersdorf J. P., Xie Z., Zeidan A. M. 2023Cancer J. 29(3):195–202. doi: 10.1097/PPO.0000000000000658. <a href="https://doi.org/10.1097/PPO.0000000000000658" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1097/PPO.0000000000000658</a></cite> [<a href="https://doi.org/10.1097/PPO.0000000000000658" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37195776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20J&amp;title=Novel%20approaches%20and%20future%20directions%20in%20myelodysplastic%20syndrome%20treatment&amp;author=J.%20P.%20Bewersdorf&amp;author=Z.%20Xie&amp;author=A.%20M.%20Zeidan&amp;volume=29&amp;issue=3&amp;pages=195-202&amp;pmid=37195776&amp;doi=10.1097/PPO.0000000000000658&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477395">
<span class="label">31.</span><cite>Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Zeidan A. M., Stahl M., Hu X.., et al.  2018Blood. 131(7):818–821. doi: 10.1182/blood-2017-10-811729. <a href="https://doi.org/10.1182/blood-2017-10-811729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2017-10-811729</a></cite> [<a href="https://doi.org/10.1182/blood-2017-10-811729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6410557/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29259002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Long-term%20survival%20of%20older%20patients%20with%20MDS%20treated%20with%20HMA%20therapy%20without%20subsequent%20stem%20cell%20transplantation&amp;author=A.%20M.%20Zeidan&amp;author=M.%20Stahl&amp;author=X..%20Hu&amp;volume=131&amp;issue=7&amp;pages=818-821&amp;pmid=29259002&amp;doi=10.1182/blood-2017-10-811729&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477396">
<span class="label">32.</span><cite>Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: Are we using realistic estimates? Zeidan A. M., Stahl M., DeVeaux M.., et al.  Jun 11;2018 Blood Cancer J. 8(6):55. doi: 10.1038/s41408-018-0081-8. <a href="https://doi.org/10.1038/s41408-018-0081-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41408-018-0081-8</a></cite> [<a href="https://doi.org/10.1038/s41408-018-0081-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5995881/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29891916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&amp;title=Counseling%20patients%20with%20higher-risk%20MDS%20regarding%20survival%20with%20azacitidine%20therapy:%20Are%20we%20using%20realistic%20estimates?&amp;author=A.%20M.%20Zeidan&amp;author=M.%20Stahl&amp;author=M..%20DeVeaux&amp;volume=8&amp;issue=6&amp;pages=55&amp;pmid=29891916&amp;doi=10.1038/s41408-018-0081-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477397">
<span class="label">33.</span><cite>A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Zeidan A. M., Smith B. D., Carraway H. E.., et al.  2017Br J Haematol. 176(2):241–247. doi: 10.1111/bjh.14407. <a href="https://doi.org/10.1111/bjh.14407" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1111/bjh.14407</a></cite> [<a href="https://doi.org/10.1111/bjh.14407" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27790720/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Haematol&amp;title=A%20phase%202%20trial%20of%20high%20dose%20lenalidomide%20in%20patients%20with%20relapsed/refractory%20higher-risk%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukaemia%20with%20trilineage%20dysplasia&amp;author=A.%20M.%20Zeidan&amp;author=B.%20D.%20Smith&amp;author=H.%20E..%20Carraway&amp;volume=176&amp;issue=2&amp;pages=241-247&amp;pmid=27790720&amp;doi=10.1111/bjh.14407&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477398">
<span class="label">34.</span><cite>Venetoclax and azacitidine in the treatment of patients with relapsed/refractory myelodysplastic syndrome. Zeidan A. M., Borate U., Pollyea D. A.., et al.  2021Blood. 138(suppl 1):537–537. doi: 10.1182/blood-2021-145646. <a href="https://doi.org/10.1182/blood-2021-145646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2021-145646</a></cite> [<a href="https://doi.org/10.1182/blood-2021-145646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Venetoclax%20and%20azacitidine%20in%20the%20treatment%20of%20patients%20with%20relapsed/refractory%20myelodysplastic%20syndrome&amp;author=A.%20M.%20Zeidan&amp;author=U.%20Borate&amp;author=D.%20A..%20Pollyea&amp;volume=138&amp;issue=suppl%201&amp;pages=537-537&amp;doi=10.1182/blood-2021-145646&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477399">
<span class="label">35.</span><cite>A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Zeidan A. M., Borate U., Pollyea D. A.., et al.  2023Am J Hematol. 98(2):272–281. doi: 10.1002/ajh.26771. <a href="https://doi.org/10.1002/ajh.26771" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1002/ajh.26771</a></cite> [<a href="https://doi.org/10.1002/ajh.26771" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10100228/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36309981/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Hematol&amp;title=A%20phase%201b%20study%20of%20venetoclax%20and%20azacitidine%20combination%20in%20patients%20with%20relapsed%20or%20refractory%20myelodysplastic%20syndromes&amp;author=A.%20M.%20Zeidan&amp;author=U.%20Borate&amp;author=D.%20A..%20Pollyea&amp;volume=98&amp;issue=2&amp;pages=272-281&amp;pmid=36309981&amp;doi=10.1002/ajh.26771&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477400">
<span class="label">36.</span><cite>Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. Knaus H. A., Berglund S., Hackl H.., et al.  Nov 2;2018 JCI Insight. 3(21):e120974. doi: 10.1172/jci.insight.120974. <a href="https://doi.org/10.1172/jci.insight.120974" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1172/jci.insight.120974</a></cite> [<a href="https://doi.org/10.1172/jci.insight.120974" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6238744/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30385732/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCI%20Insight&amp;title=Signatures%20of%20CD8+%20T%20cell%20dysfunction%20in%20AML%20patients%20and%20their%20reversibility%20with%20response%20to%20chemotherapy&amp;author=H.%20A.%20Knaus&amp;author=S.%20Berglund&amp;author=H..%20Hackl&amp;volume=3&amp;issue=21&amp;pages=e120974&amp;pmid=30385732&amp;doi=10.1172/jci.insight.120974&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477401">
<span class="label">37.</span><cite>Ipilimumab for patients with relapse after allogeneic transplantation. Davids M. S., Kim H. T., Bachireddy P.., et al.  2016N Engl J Med. 375(2):143–153. doi: 10.1056/NEJMoa1601202. <a href="https://doi.org/10.1056/NEJMoa1601202" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1056/NEJMoa1601202</a></cite> [<a href="https://doi.org/10.1056/NEJMoa1601202" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5149459/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27410923/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Ipilimumab%20for%20patients%20with%20relapse%20after%20allogeneic%20transplantation&amp;author=M.%20S.%20Davids&amp;author=H.%20T.%20Kim&amp;author=P..%20Bachireddy&amp;volume=375&amp;issue=2&amp;pages=143-153&amp;pmid=27410923&amp;doi=10.1056/NEJMoa1601202&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477402">
<span class="label">38.</span><cite>A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Zeidan A. M., Knaus H. A., Robinson T. M.., et al.  2018Clin Cancer Res. 24(15):3519–3527. doi: 10.1158/1078-0432.CCR-17-3763. <a href="https://doi.org/10.1158/1078-0432.CCR-17-3763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1158/1078-0432.CCR-17-3763</a></cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-3763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6680246/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29716921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=A%20multi-center%20phase%20I%20trial%20of%20ipilimumab%20in%20patients%20with%20myelodysplastic%20syndromes%20following%20hypomethylating%20agent%20failure&amp;author=A.%20M.%20Zeidan&amp;author=H.%20A.%20Knaus&amp;author=T.%20M..%20Robinson&amp;volume=24&amp;issue=15&amp;pages=3519-3527&amp;pmid=29716921&amp;doi=10.1158/1078-0432.CCR-17-3763&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477403">
<span class="label">39.</span><cite>A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Zeidan A. M., Boss I., Beach C. L.., et al.  2022Blood Adv. 6(7):2219–2229. doi: 10.1182/bloodadvances.2021006138. <a href="https://doi.org/10.1182/bloodadvances.2021006138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/bloodadvances.2021006138</a></cite> [<a href="https://doi.org/10.1182/bloodadvances.2021006138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9006260/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34933333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=A%20randomized%20phase%202%20trial%20of%20azacitidine%20with%20or%20without%20durvalumab%20as%20first-line%20therapy%20for%20older%20patients%20with%20AML&amp;author=A.%20M.%20Zeidan&amp;author=I.%20Boss&amp;author=C.%20L..%20Beach&amp;volume=6&amp;issue=7&amp;pages=2219-2229&amp;pmid=34933333&amp;doi=10.1182/bloodadvances.2021006138&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477404">
<span class="label">40.</span><cite>Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Lu S.X., De Neef E., Thomas J.D.., et al.  2021Cell. 184(15):4032–4047.e31. doi: 10.1016/j.cell.2021.05.038. <a href="https://doi.org/10.1016/j.cell.2021.05.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.cell.2021.05.038</a></cite> [<a href="https://doi.org/10.1016/j.cell.2021.05.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8684350/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34171309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Pharmacologic%20modulation%20of%20RNA%20splicing%20enhances%20anti-tumor%20immunity&amp;author=S.X.%20Lu&amp;author=E.%20De%20Neef&amp;author=J.D..%20Thomas&amp;volume=184&amp;issue=15&amp;pages=4032-4047.e31&amp;pmid=34171309&amp;doi=10.1016/j.cell.2021.05.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477405">
<span class="label">41.</span><cite>Impact of allelic state on overall survival in TP53-mutant acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS) Bewersdorf J. P., Hasle V., Shallis R. M.., et al.  2022Blood. 140(suppl 1):8910–8911. doi: 10.1182/blood-2022-158592. <a href="https://doi.org/10.1182/blood-2022-158592" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2022-158592</a></cite> [<a href="https://doi.org/10.1182/blood-2022-158592" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Impact%20of%20allelic%20state%20on%20overall%20survival%20in%20TP53-mutant%20acute%20myeloid%20leukemia%20(AML)%20and%20higher%20risk%20myelodysplastic%20syndromes%20(HR-MDS)&amp;author=J.%20P.%20Bewersdorf&amp;author=V.%20Hasle&amp;author=R.%20M..%20Shallis&amp;volume=140&amp;issue=suppl%201&amp;pages=8910-8911&amp;doi=10.1182/blood-2022-158592&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477406">
<span class="label">42.</span><cite>A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Bewersdorf J. P., Shallis R. M., Sharon E.., et al.  2024Ann Hematol. 103(1):105–116. doi: 10.1007/s00277-023-05552-4. <a href="https://doi.org/10.1007/s00277-023-05552-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1007/s00277-023-05552-4</a></cite> [<a href="https://doi.org/10.1007/s00277-023-05552-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11838822/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38036712/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Hematol&amp;title=A%20multicenter%20phase%20Ib%20trial%20of%20the%20histone%20deacetylase%20inhibitor%20entinostat%20in%20combination%20with%20pembrolizumab%20in%20patients%20with%20myelodysplastic%20syndromes/neoplasms%20or%20acute%20myeloid%20leukemia%20refractory%20to%20hypomethylating%20agents&amp;author=J.%20P.%20Bewersdorf&amp;author=R.%20M.%20Shallis&amp;author=E..%20Sharon&amp;volume=103&amp;issue=1&amp;pages=105-116&amp;pmid=38036712&amp;doi=10.1007/s00277-023-05552-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477407">
<span class="label">43.</span><cite>How we treat higher-risk myelodysplastic syndromes. Sekeres M. A., Cutler C. 2014Blood. 123(6):829–836. doi: 10.1182/blood-2013-08-496935. <a href="https://doi.org/10.1182/blood-2013-08-496935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2013-08-496935</a></cite> [<a href="https://doi.org/10.1182/blood-2013-08-496935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24363399/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=How%20we%20treat%20higher-risk%20myelodysplastic%20syndromes&amp;author=M.%20A.%20Sekeres&amp;author=C.%20Cutler&amp;volume=123&amp;issue=6&amp;pages=829-836&amp;pmid=24363399&amp;doi=10.1182/blood-2013-08-496935&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477408">
<span class="label">44.</span><cite>Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (pts) with higher-risk (HR) myelodysplastic syndromes (MDS): Efficacy and safety results in HMA treatment naïve &amp; relapsed (Rel)/refractory (Ref) patients. Navada S.C., Garcia-Manero G., Atallah E.., et al.  2018Blood. 132(suppl 1):230–230. doi: 10.1182/blood-2018-99-119259. <a href="https://doi.org/10.1182/blood-2018-99-119259" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2018-99-119259</a></cite> [<a href="https://doi.org/10.1182/blood-2018-99-119259" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Phase%202%20expansion%20study%20of%20oral%20rigosertib%20combined%20with%20azacitidine%20(AZA)%20in%20patients%20(pts)%20with%20higher-risk%20(HR)%20myelodysplastic%20syndromes%20(MDS):%20Efficacy%20and%20safety%20results%20in%20HMA%20treatment%20na%C3%AFve%20&amp;%20relapsed%20(Rel)/refractory%20(Ref)%20patients&amp;author=S.C.%20Navada&amp;author=G.%20Garcia-Manero&amp;author=E..%20Atallah&amp;volume=132&amp;issue=suppl%201&amp;pages=230-230&amp;doi=10.1182/blood-2018-99-119259&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477409">
<span class="label">45.</span><cite>Treatment of high-risk myelodysplastic syndromes. Kröger N. Feb 1;2025 Haematologica. 110(2):339–349. doi: 10.3324/haematol.2023.284946. <a href="https://doi.org/10.3324/haematol.2023.284946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3324/haematol.2023.284946</a></cite> [<a href="https://doi.org/10.3324/haematol.2023.284946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11788630/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39633555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Treatment%20of%20high-risk%20myelodysplastic%20syndromes&amp;author=N.%20Kr%C3%B6ger&amp;volume=110&amp;issue=2&amp;pages=339-349&amp;pmid=39633555&amp;doi=10.3324/haematol.2023.284946&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477410">
<span class="label">46.</span><cite>Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Schwartz S., Patel N., Longmire T.., et al.  Aug 10;2022 Immunother Adv. 2(1):ltac019. doi: 10.1093/immadv/ltac019. <a href="https://doi.org/10.1093/immadv/ltac019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/immadv/ltac019</a></cite> [<a href="https://doi.org/10.1093/immadv/ltac019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9525012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36196369/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunother%20Adv&amp;title=Characterization%20of%20sabatolimab,%20a%20novel%20immunotherapy%20with%20immuno-myeloid%20activity%20directed%20against%20TIM-3%20receptor&amp;author=S.%20Schwartz&amp;author=N.%20Patel&amp;author=T..%20Longmire&amp;volume=2&amp;issue=1&amp;pages=ltac019&amp;pmid=36196369&amp;doi=10.1093/immadv/ltac019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477411">
<span class="label">47.</span><cite>The STIMULUS Program: Clinical trials evaluating sabatolimab (MBG453) combination therapy in patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML) Zeidan A. M., Esteve J., Giagounidis A.., et al.  2020Blood. 136(suppl 1):45–46. doi: 10.1182/blood-2020-134718. <a href="https://doi.org/10.1182/blood-2020-134718" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2020-134718</a></cite> [<a href="https://doi.org/10.1182/blood-2020-134718" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20STIMULUS%20Program:%20Clinical%20trials%20evaluating%20sabatolimab%20(MBG453)%20combination%20therapy%20in%20patients%20(pts)%20with%20higher-risk%20myelodysplastic%20syndromes%20(HR-MDS)%20or%20acute%20myeloid%20leukemia%20(AML)&amp;author=A.%20M.%20Zeidan&amp;author=J.%20Esteve&amp;author=A..%20Giagounidis&amp;volume=136&amp;issue=suppl%201&amp;pages=45-46&amp;doi=10.1182/blood-2020-134718&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477412">
<span class="label">48.</span><cite>Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): A randomised, double-blind, placebo-controlled, phase 2 trial. Zeidan A. M., Ando K., Rauzy O.., et al.  2024Lancet Haematol. 11(1):e38–e50. doi: 10.1016/S2352-3026(23)00333-2. <a href="https://doi.org/10.1016/S2352-3026(23)00333-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/S2352-3026(23)00333-2</a></cite> [<a href="https://doi.org/10.1016/S2352-3026(23)00333-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38065203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Sabatolimab%20plus%20hypomethylating%20agents%20in%20previously%20untreated%20patients%20with%20higher-risk%20myelodysplastic%20syndromes%20(STIMULUS-MDS1):%20A%20randomised,%20double-blind,%20placebo-controlled,%20phase%202%20trial&amp;author=A.%20M.%20Zeidan&amp;author=K.%20Ando&amp;author=O..%20Rauzy&amp;volume=11&amp;issue=1&amp;pages=e38-e50&amp;pmid=38065203&amp;doi=10.1016/S2352-3026(23)00333-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477413">
<span class="label">49.</span><cite>STIMULUS-MDS2 design and rationale: A phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Zeidan A. M., Giagounidis A., Sekeres M. A.., et al.  2023Future Oncol. 19(9):631–642. doi: 10.2217/fon-2022-1237. <a href="https://doi.org/10.2217/fon-2022-1237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.2217/fon-2022-1237</a></cite> [<a href="https://doi.org/10.2217/fon-2022-1237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37083373/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Future%20Oncol&amp;title=STIMULUS-MDS2%20design%20and%20rationale:%20A%20phase%20III%20trial%20with%20the%20anti-TIM-3%20sabatolimab%20(MBG453)%20+%20azacitidine%20in%20higher%20risk%20MDS%20and%20CMML-2&amp;author=A.%20M.%20Zeidan&amp;author=A.%20Giagounidis&amp;author=M.%20A..%20Sekeres&amp;volume=19&amp;issue=9&amp;pages=631-642&amp;pmid=37083373&amp;doi=10.2217/fon-2022-1237&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477440">
<span class="label">50.</span><cite>Targeting LAG-3, TIM-3, and TIGIT for Cancer Immunotherapy. Cai Linyuan., et al.  Sep 5;2023 Journal of Hematology &amp; Oncology. 16(1) doi: 10.1186/s13045-023-01499-1. <a href="https://doi.org/10.1186/s13045-023-01499-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1186/s13045-023-01499-1</a></cite> [<a href="https://doi.org/10.1186/s13045-023-01499-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10478462/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37670328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Hematology%20&amp;%20Oncology&amp;title=Targeting%20LAG-3,%20TIM-3,%20and%20TIGIT%20for%20Cancer%20Immunotherapy&amp;author=Linyuan.%20Cai&amp;volume=16&amp;issue=1&amp;pmid=37670328&amp;doi=10.1186/s13045-023-01499-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477441">
<span class="label">51.</span><cite>Myeloid Immunosuppression and Immune Checkpoints in the Tumor Microenvironment. Nakamura Kyohei, Smyth Mark J. Oct 14;2019  [2025-6-19];Cellular &amp; Molecular Immunology. 17(1):1–12. doi: 10.1038/s41423-019-0306-1. <a href="https://doi.org/10.1038/s41423-019-0306-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41423-019-0306-1</a></cite> [<a href="https://doi.org/10.1038/s41423-019-0306-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6952382/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31611651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cellular%20&amp;%20Molecular%20Immunology&amp;title=Myeloid%20Immunosuppression%20and%20Immune%20Checkpoints%20in%20the%20Tumor%20Microenvironment&amp;author=Kyohei%20Nakamura&amp;author=Mark%20J.%20Smyth&amp;volume=17&amp;issue=1&amp;pages=1-12&amp;pmid=31611651&amp;doi=10.1038/s41423-019-0306-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477414">
<span class="label">52.</span><cite>An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Soucy T. A., Smith P. G., Milhollen M. A.., et al.  2009Nature. 458(7239):732–736. doi: 10.1038/nature07884. <a href="https://doi.org/10.1038/nature07884" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/nature07884</a></cite> [<a href="https://doi.org/10.1038/nature07884" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19360080/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=An%20inhibitor%20of%20NEDD8-activating%20enzyme%20as%20a%20new%20approach%20to%20treat%20cancer&amp;author=T.%20A.%20Soucy&amp;author=P.%20G.%20Smith&amp;author=M.%20A..%20Milhollen&amp;volume=458&amp;issue=7239&amp;pages=732-736&amp;pmid=19360080&amp;doi=10.1038/nature07884&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477415">
<span class="label">53.</span><cite>The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Soucy T. A., Dick L. R., Smith P. G.., et al.  2010Genes Cancer. 1(7):708–716. doi: 10.1177/1947601910382898. <a href="https://doi.org/10.1177/1947601910382898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1177/1947601910382898</a></cite> [<a href="https://doi.org/10.1177/1947601910382898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3092238/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21779466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes%20Cancer&amp;title=The%20NEDD8%20conjugation%20pathway%20and%20its%20relevance%20in%20cancer%20biology%20and%20therapy&amp;author=T.%20A.%20Soucy&amp;author=L.%20R.%20Dick&amp;author=P.%20G..%20Smith&amp;volume=1&amp;issue=7&amp;pages=708-716&amp;pmid=21779466&amp;doi=10.1177/1947601910382898&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477416">
<span class="label">54.</span><cite>Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Sekeres M. A., Watts J., Radinoff A.., et al.  2021Leukemia. 35(7):2119–2124. doi: 10.1038/s41375-021-01125-4. <a href="https://doi.org/10.1038/s41375-021-01125-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41375-021-01125-4</a></cite> [<a href="https://doi.org/10.1038/s41375-021-01125-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8257476/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33483617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Randomized%20phase%202%20trial%20of%20pevonedistat%20plus%20azacitidine%20versus%20azacitidine%20for%20higher-risk%20MDS/CMML%20or%20low-blast%20AML&amp;author=M.%20A.%20Sekeres&amp;author=J.%20Watts&amp;author=A..%20Radinoff&amp;volume=35&amp;issue=7&amp;pages=2119-2124&amp;pmid=33483617&amp;doi=10.1038/s41375-021-01125-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477417">
<span class="label">55.</span><cite>Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Adès L., Girshova L., Doronin V. A.., et al.  2022Blood Adv. 6(17):5132–5145. doi: 10.1182/bloodadvances.2022007334. <a href="https://doi.org/10.1182/bloodadvances.2022007334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/bloodadvances.2022007334</a></cite> [<a href="https://doi.org/10.1182/bloodadvances.2022007334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9631625/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35728048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Pevonedistat%20plus%20azacitidine%20vs%20azacitidine%20alone%20in%20higher-risk%20MDS/chronic%20myelomonocytic%20leukemia%20or%20low-blast-percentage%20AML&amp;author=L.%20Ad%C3%A8s&amp;author=L.%20Girshova&amp;author=V.%20A..%20Doronin&amp;volume=6&amp;issue=17&amp;pages=5132-5145&amp;pmid=35728048&amp;doi=10.1182/bloodadvances.2022007334&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477442">
<span class="label">56.</span><cite>Pevonedistat plus Azacitidine vs Azacitidine Alone in Higher-Risk MDS/Chronic Myelomonocytic Leukemia or Low-Blast-Percentage AML. Adès Lionel., et al.  Sep 2;2022  [2025-6-18];Blood Advances. 6(17):5132–5145. doi: 10.1182/bloodadvances.2022007334. <a href="https://doi.org/10.1182/bloodadvances.2022007334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/bloodadvances.2022007334</a></cite> [<a href="https://doi.org/10.1182/bloodadvances.2022007334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9631625/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35728048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Advances&amp;title=Pevonedistat%20plus%20Azacitidine%20vs%20Azacitidine%20Alone%20in%20Higher-Risk%20MDS/Chronic%20Myelomonocytic%20Leukemia%20or%20Low-Blast-Percentage%20AML&amp;author=Lionel.%20Ad%C3%A8s&amp;volume=6&amp;issue=17&amp;pages=5132-5145&amp;pmid=35728048&amp;doi=10.1182/bloodadvances.2022007334&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477418">
<span class="label">57.</span><cite>Myelodysplastic neoplasms (MDS): The current and future treatment landscape. Karel D., Valburg C., Woddor N.., et al.  Apr 3;2024 Curr Oncol. 31(4):1971–1993. doi: 10.3390/curroncol31040148. <a href="https://doi.org/10.3390/curroncol31040148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3390/curroncol31040148</a></cite> [<a href="https://doi.org/10.3390/curroncol31040148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11049094/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38668051/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Oncol&amp;title=Myelodysplastic%20neoplasms%20(MDS):%20The%20current%20and%20future%20treatment%20landscape&amp;author=D.%20Karel&amp;author=C.%20Valburg&amp;author=N..%20Woddor&amp;volume=31&amp;issue=4&amp;pages=1971-1993&amp;pmid=38668051&amp;doi=10.3390/curroncol31040148&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477419">
<span class="label">58.</span><cite>Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. Sallman D. A., DeZern A. E., Garcia-Manero G.., et al.  2021J Clin Oncol. 39(14):1584–1594. doi: 10.1200/JCO.20.02341. <a href="https://doi.org/10.1200/JCO.20.02341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1200/JCO.20.02341</a></cite> [<a href="https://doi.org/10.1200/JCO.20.02341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8099410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33449813/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Eprenetapopt%20(APR-246)%20and%20azacitidine%20in%20TP53-mutant%20myelodysplastic%20syndromes&amp;author=D.%20A.%20Sallman&amp;author=A.%20E.%20DeZern&amp;author=G..%20Garcia-Manero&amp;volume=39&amp;issue=14&amp;pages=1584-1594&amp;pmid=33449813&amp;doi=10.1200/JCO.20.02341&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477443">
<span class="label">59.</span><cite>The Mutant P53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. Dec 1;2018  [2025-6-19];Translational Oncology. 11(6):1343–1349. doi: 10.1016/j.tranon.2018.08.009. <a href="https://doi.org/10.1016/j.tranon.2018.08.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.tranon.2018.08.009</a></cite> [<a href="https://doi.org/10.1016/j.tranon.2018.08.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6132178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30196236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Translational%20Oncology&amp;title=The%20Mutant%20P53-Targeting%20Compound%20APR-246%20Induces%20ROS-Modulating%20Genes%20in%20Breast%20Cancer%20Cells&amp;volume=11&amp;issue=6&amp;pages=1343-1349&amp;pmid=30196236&amp;doi=10.1016/j.tranon.2018.08.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477420">
<span class="label">60.</span><cite>Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Cortes J. E., Heidel F. H., Hellmann A.., et al.  2019Leukemia. 33(2):379–389. doi: 10.1038/s41375-018-0312-9. <a href="https://doi.org/10.1038/s41375-018-0312-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41375-018-0312-9</a></cite> [<a href="https://doi.org/10.1038/s41375-018-0312-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6365492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30555165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Randomized%20comparison%20of%20low%20dose%20cytarabine%20with%20or%20without%20glasdegib%20in%20patients%20with%20newly%20diagnosed%20acute%20myeloid%20leukemia%20or%20high-risk%20myelodysplastic%20syndrome&amp;author=J.%20E.%20Cortes&amp;author=F.%20H.%20Heidel&amp;author=A..%20Hellmann&amp;volume=33&amp;issue=2&amp;pages=379-389&amp;pmid=30555165&amp;doi=10.1038/s41375-018-0312-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477444">
<span class="label">61.</span><cite>Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Savona Michael R.., et al.  Feb 20;2018  [2025-6-19];Clinical Cancer Research. 24(10):2294–2303. doi: 10.1158/1078-0432.ccr-17-2824. <a href="https://doi.org/10.1158/1078-0432.ccr-17-2824" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1158/1078-0432.ccr-17-2824</a></cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-17-2824" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29463550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Cancer%20Research&amp;title=Phase%20Ib%20Study%20of%20Glasdegib,%20a%20Hedgehog%20Pathway%20Inhibitor,%20in%20Combination%20with%20Standard%20Chemotherapy%20in%20Patients%20with%20AML%20or%20High-Risk%20MDS&amp;author=Michael%20R..%20Savona&amp;volume=24&amp;issue=10&amp;pages=2294-2303&amp;pmid=29463550&amp;doi=10.1158/1078-0432.ccr-17-2824&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477421">
<span class="label">62.</span><cite>Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial. Garcia-Manero G., Fenaux P., Al-Kali A.., et al.  2016Lancet Oncol. 17(4):496–508. doi: 10.1016/S1470-2045(16)00009-7. <a href="https://doi.org/10.1016/S1470-2045(16)00009-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/S1470-2045(16)00009-7</a></cite> [<a href="https://doi.org/10.1016/S1470-2045(16)00009-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26968357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Rigosertib%20versus%20best%20supportive%20care%20for%20patients%20with%20high-risk%20myelodysplastic%20syndromes%20after%20failure%20of%20hypomethylating%20drugs%20(ONTIME):%20A%20randomised,%20controlled,%20phase%203%20trial&amp;author=G.%20Garcia-Manero&amp;author=P.%20Fenaux&amp;author=A..%20Al-Kali&amp;volume=17&amp;issue=4&amp;pages=496-508&amp;pmid=26968357&amp;doi=10.1016/S1470-2045(16)00009-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477422">
<span class="label">63.</span><cite>Amelioration of rigosertib treatment-related genitourinary (GU) adverse events (AEs) in patients with myelodysplastic syndromes: Implementation of novel dosing regimen derived through pharmacokinetic modeling in phase 2 study of oral rigosertib in combination with azacitidine. Taft D., Vora T., Ren C.., et al.  2018Blood. 132(suppl 1):4379. doi: 10.1182/blood-2018-99-118463. <a href="https://doi.org/10.1182/blood-2018-99-118463" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2018-99-118463</a></cite> [<a href="https://doi.org/10.1182/blood-2018-99-118463" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Amelioration%20of%20rigosertib%20treatment-related%20genitourinary%20(GU)%20adverse%20events%20(AEs)%20in%20patients%20with%20myelodysplastic%20syndromes:%20Implementation%20of%20novel%20dosing%20regimen%20derived%20through%20pharmacokinetic%20modeling%20in%20phase%202%20study%20of%20oral%20rigosertib%20in%20combination%20with%20azacitidine&amp;author=D.%20Taft&amp;author=T.%20Vora&amp;author=C..%20Ren&amp;volume=132&amp;issue=suppl%201&amp;pages=4379&amp;doi=10.1182/blood-2018-99-118463&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477445">
<span class="label">64.</span><cite>Rigosertib versus Best Supportive Care for Patients with High-Risk Myelodysplastic Syndromes after Failure of Hypomethylating Drugs (ONTIME): A Randomised, Controlled, Phase 3 Trial. Garcia-Manero Guillermo., et al.  Apr 1;2016  [2025-6-19];17(4):496–508. doi: 10.1016/s1470-2045(16)00009-7. <a href="https://doi.org/10.1016/s1470-2045(16)00009-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/s1470-2045(16)00009-7</a></cite> [<a href="https://doi.org/10.1016/s1470-2045(16)00009-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26968357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rigosertib%20versus%20Best%20Supportive%20Care%20for%20Patients%20with%20High-Risk%20Myelodysplastic%20Syndromes%20after%20Failure%20of%20Hypomethylating%20Drugs%20(ONTIME):%20A%20Randomised,%20Controlled,%20Phase%203%20Trial.%20Garcia-Manero%20Guillermo.,%20et%20al.%20Apr%201;2016%20%5B2025-6-19%5D;17(4):496%E2%80%93508.%20doi:%2010.1016/s1470-2045(16)00009-7.%20https://doi.org/10.1016/s1470-2045(16)00009-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477423">
<span class="label">65.</span><cite>Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study. Sallman D. A., Al Malki M. M., Asch A. S.., et al.  2023J Clin Oncol. 41(15):2815–2826. doi: 10.1200/JCO.22.01794. <a href="https://doi.org/10.1200/JCO.22.01794" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1200/JCO.22.01794</a></cite> [<a href="https://doi.org/10.1200/JCO.22.01794" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10414740/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36888930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Magrolimab%20in%20combination%20with%20azacitidine%20in%20patients%20with%20higher-risk%20myelodysplastic%20syndromes:%20Final%20results%20of%20a%20phase%20Ib%20study&amp;author=D.%20A.%20Sallman&amp;author=M.%20M.%20Al%20Malki&amp;author=A.%20S..%20Asch&amp;volume=41&amp;issue=15&amp;pages=2815-2826&amp;pmid=36888930&amp;doi=10.1200/JCO.22.01794&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477424">
<span class="label">66.</span><cite>Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study. Garcia-Manero G., Jabbour E., Xu J.., et al.  2021J Clin Oncol. 39(15 suppl):TPS7055–TPS7055. doi: 10.1200/jco.2021.39.15_suppl.tps7055. <a href="https://doi.org/10.1200/jco.2021.39.15_suppl.tps7055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1200/jco.2021.39.15_suppl.tps7055</a></cite> [<a href="https://doi.org/10.1200/jco.2021.39.15_suppl.tps7055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Magrolimab%20+%20azacitidine%20versus%20azacitidine%20+%20placebo%20in%20untreated%20higher%20risk%20(HR)%20myelodysplastic%20syndrome%20(MDS):%20The%20phase%203,%20randomized,%20ENHANCE%20study&amp;author=G.%20Garcia-Manero&amp;author=E.%20Jabbour&amp;author=J..%20Xu&amp;volume=39&amp;issue=15%20suppl&amp;pages=TPS7055-TPS7055&amp;doi=10.1200/jco.2021.39.15_suppl.tps7055&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477446">
<span class="label">67.</span><cite>Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms. Gerke Margo Brooke., et al.  Jul 27;2023 Cancers. 15(15):3815–3815. doi: 10.3390/cancers15153815. <a href="https://doi.org/10.3390/cancers15153815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3390/cancers15153815</a></cite> [<a href="https://doi.org/10.3390/cancers15153815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10417399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37568631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Definitions,%20Biology,%20and%20Current%20Therapeutic%20Landscape%20of%20Myelodysplastic/Myeloproliferative%20Neoplasms&amp;author=Margo%20Brooke.%20Gerke&amp;volume=15&amp;issue=15&amp;pages=3815-3815&amp;pmid=37568631&amp;doi=10.3390/cancers15153815&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477425">
<span class="label">68.</span><cite>Early results from a biomarker-directed phase 2 trial of Sy-1425 in combination with azacitidine or daratumumab in non-APL acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Cook R. J., Moyo T., Liesveld J. L.., et al.  2018Blood. 132(suppl 1):2735–2735. doi: 10.1182/blood-2018-99-111285. <a href="https://doi.org/10.1182/blood-2018-99-111285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2018-99-111285</a></cite> [<a href="https://doi.org/10.1182/blood-2018-99-111285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Early%20results%20from%20a%20biomarker-directed%20phase%202%20trial%20of%20Sy-1425%20in%20combination%20with%20azacitidine%20or%20daratumumab%20in%20non-APL%20acute%20myeloid%20leukemia%20(AML)%20and%20myelodysplastic%20syndrome%20(MDS)&amp;author=R.%20J.%20Cook&amp;author=T.%20Moyo&amp;author=J.%20L..%20Liesveld&amp;volume=132&amp;issue=suppl%201&amp;pages=2735-2735&amp;doi=10.1182/blood-2018-99-111285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477426">
<span class="label">69.</span><cite>Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. de Botton S., Cluzeau T., Vigil C.., et al.  2023Blood Adv. 7(9):1858–1870. doi: 10.1182/bloodadvances.2022008806. <a href="https://doi.org/10.1182/bloodadvances.2022008806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/bloodadvances.2022008806</a></cite> [<a href="https://doi.org/10.1182/bloodadvances.2022008806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10165187/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36477975/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Targeting%20RARA%20overexpression%20with%20tamibarotene,%20a%20potent%20and%20selective%20RAR%CE%B1%20agonist,%20is%20a%20novel%20approach%20in%20AML&amp;author=S.%20de%20Botton&amp;author=T.%20Cluzeau&amp;author=C..%20Vigil&amp;volume=7&amp;issue=9&amp;pages=1858-1870&amp;pmid=36477975&amp;doi=10.1182/bloodadvances.2022008806&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477427">
<span class="label">70.</span><cite>MDS-110 SELECT-MDS-1 Trial in progress: A phase 3 randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA-positive higher-risk MDS. DeZern A., Fenaux P., Deeren D.., et al.  2022Clin Lymphoma Myeloma Leuk. 22(suppl 2):S303–S304. doi: 10.1016/S2152-2650(22)01395-7. <a href="https://doi.org/10.1016/S2152-2650(22)01395-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/S2152-2650(22)01395-7</a></cite> [<a href="https://doi.org/10.1016/S2152-2650(22)01395-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lymphoma%20Myeloma%20Leuk&amp;title=MDS-110%20SELECT-MDS-1%20Trial%20in%20progress:%20A%20phase%203%20randomized,%20double-blind,%20placebo-controlled%20study%20of%20tamibarotene/azacitidine%20versus%20placebo/azacitidine%20in%20newly%20diagnosed%20adult%20patients%20selected%20for%20RARA-positive%20higher-risk%20MDS&amp;author=A.%20DeZern&amp;author=P.%20Fenaux&amp;author=D..%20Deeren&amp;volume=22&amp;issue=suppl%202&amp;pages=S303-S304&amp;doi=10.1016/S2152-2650(22)01395-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477447">
<span class="label">71.</span><cite>Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, Is a Novel Approach in AML. de Botton Stéphane., et al.  Apr 28;2023  [2025-6-18];Blood Advances. 7(9):1858–1870. doi: 10.1182/bloodadvances.2022008806. <a href="https://doi.org/10.1182/bloodadvances.2022008806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/bloodadvances.2022008806</a></cite> [<a href="https://doi.org/10.1182/bloodadvances.2022008806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10165187/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36477975/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Advances&amp;title=Targeting%20RARA%20Overexpression%20with%20Tamibarotene,%20a%20Potent%20and%20Selective%20RAR%CE%B1%20Agonist,%20Is%20a%20Novel%20Approach%20in%20AML&amp;author=St%C3%A9phane.%20de%20Botton&amp;volume=7&amp;issue=9&amp;pages=1858-1870&amp;pmid=36477975&amp;doi=10.1182/bloodadvances.2022008806&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477428">
<span class="label">72.</span><cite>Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. Garcia-Manero G., Ribrag V., Zhang Y.., et al.  2022Leuk Lymphoma. 63(7):1660–1668. doi: 10.1080/10428194.2022.2034155. <a href="https://doi.org/10.1080/10428194.2022.2034155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1080/10428194.2022.2034155</a></cite> [<a href="https://doi.org/10.1080/10428194.2022.2034155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35244520/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Lymphoma&amp;title=Pembrolizumab%20for%20myelodysplastic%20syndromes%20after%20failure%20of%20hypomethylating%20agents%20in%20the%20phase%201b%20KEYNOTE-013%20study&amp;author=G.%20Garcia-Manero&amp;author=V.%20Ribrag&amp;author=Y..%20Zhang&amp;volume=63&amp;issue=7&amp;pages=1660-1668&amp;pmid=35244520&amp;doi=10.1080/10428194.2022.2034155&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477429">
<span class="label">73.</span><cite>Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Chien K. S., Kim K., Nogueras-Gonzalez G. M.., et al.  2021Br J Haematol. 195(3):378–387. doi: 10.1111/bjh.17689. <a href="https://doi.org/10.1111/bjh.17689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1111/bjh.17689</a></cite> [<a href="https://doi.org/10.1111/bjh.17689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34340254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Haematol&amp;title=Phase%20II%20study%20of%20azacitidine%20with%20pembrolizumab%20in%20patients%20with%20intermediate-1%20or%20higher-risk%20myelodysplastic%20syndrome&amp;author=K.%20S.%20Chien&amp;author=K.%20Kim&amp;author=G.%20M..%20Nogueras-Gonzalez&amp;volume=195&amp;issue=3&amp;pages=378-387&amp;pmid=34340254&amp;doi=10.1111/bjh.17689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477430">
<span class="label">74.</span><cite>A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Davids M. S., Kim H. T., Costello C.., et al.  2020Blood. 135(24):2182–2191. doi: 10.1182/blood.2019004710. <a href="https://doi.org/10.1182/blood.2019004710" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood.2019004710</a></cite> [<a href="https://doi.org/10.1182/blood.2019004710" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7290092/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32478814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20multicenter%20phase%201%20study%20of%20nivolumab%20for%20relapsed%20hematologic%20malignancies%20after%20allogeneic%20transplantation&amp;author=M.%20S.%20Davids&amp;author=H.%20T.%20Kim&amp;author=C..%20Costello&amp;volume=135&amp;issue=24&amp;pages=2182-2191&amp;pmid=32478814&amp;doi=10.1182/blood.2019004710&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477431">
<span class="label">75.</span><cite>A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Zeidan A. M., Boss I., Beach C. L.., et al.  2022Blood Adv. 6(7):2207–2218. doi: 10.1182/bloodadvances.2021005487. <a href="https://doi.org/10.1182/bloodadvances.2021005487" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/bloodadvances.2021005487</a></cite> [<a href="https://doi.org/10.1182/bloodadvances.2021005487" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9006291/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34972214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=A%20randomized%20phase%202%20trial%20of%20azacitidine%20with%20or%20without%20durvalumab%20as%20first-line%20therapy%20for%20higher-risk%20myelodysplastic%20syndromes&amp;author=A.%20M.%20Zeidan&amp;author=I.%20Boss&amp;author=C.%20L..%20Beach&amp;volume=6&amp;issue=7&amp;pages=2207-2218&amp;pmid=34972214&amp;doi=10.1182/bloodadvances.2021005487&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477432">
<span class="label">76.</span><cite>A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Zeidan A. M., Knaus H. A., Robinson T. M.., et al.  2018Clin Cancer Res. 24(15):3519–3527. doi: 10.1158/1078-0432.CCR-17-3763. <a href="https://doi.org/10.1158/1078-0432.CCR-17-3763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1158/1078-0432.CCR-17-3763</a></cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-3763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6680246/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29716921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=A%20multi-center%20phase%20I%20trial%20of%20ipilimumab%20in%20patients%20with%20myelodysplastic%20syndromes%20following%20hypomethylating%20agent%20failure&amp;author=A.%20M.%20Zeidan&amp;author=H.%20A.%20Knaus&amp;author=T.%20M..%20Robinson&amp;volume=24&amp;issue=15&amp;pages=3519-3527&amp;pmid=29716921&amp;doi=10.1158/1078-0432.CCR-17-3763&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477433">
<span class="label">77.</span><cite>The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification. Peng X., Zhu X., Di T.., et al.  Sep 23;2022 Front Immunol. 13:994053. doi: 10.3389/fimmu.2022.994053. <a href="https://doi.org/10.3389/fimmu.2022.994053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3389/fimmu.2022.994053</a></cite> [<a href="https://doi.org/10.3389/fimmu.2022.994053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9537682/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36211357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=The%20yin-yang%20of%20immunity:%20Immune%20dysregulation%20in%20myelodysplastic%20syndrome%20with%20different%20risk%20stratification&amp;author=X.%20Peng&amp;author=X.%20Zhu&amp;author=T..%20Di&amp;volume=13&amp;pages=994053&amp;pmid=36211357&amp;doi=10.3389/fimmu.2022.994053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477434">
<span class="label">78.</span><cite>A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS) Garcia-Manero G., Sasaki K., Montalban-Bravo G.., et al.  2018Blood. 132(suppl 1):465–465. doi: 10.1182/blood-2018-99-119424. <a href="https://doi.org/10.1182/blood-2018-99-119424" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2018-99-119424</a></cite> [<a href="https://doi.org/10.1182/blood-2018-99-119424" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20phase%20II%20study%20of%20nivolumab%20or%20ipilimumab%20with%20or%20without%20azacitidine%20for%20patients%20with%20myelodysplastic%20syndrome%20(MDS)&amp;author=G.%20Garcia-Manero&amp;author=K.%20Sasaki&amp;author=G..%20Montalban-Bravo&amp;volume=132&amp;issue=suppl%201&amp;pages=465-465&amp;doi=10.1182/blood-2018-99-119424&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477435">
<span class="label">79.</span><cite>The combination of AXL inhibitor bemcentinib and low dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II Trial ( <a href="https://clinicaltrials.gov/ct2/show/NCT02488408" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02488408</a>) Loges S., Heuser M., Chromik J.., et al.  2020Blood. 136(suppl 1):14–14. doi: 10.1182/blood-2020-136566. <a href="https://doi.org/10.1182/blood-2020-136566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2020-136566</a></cite> [<a href="https://doi.org/10.1182/blood-2020-136566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20combination%20of%20AXL%20inhibitor%20bemcentinib%20and%20low%20dose%20cytarabine%20is%20well%20tolerated%20and%20efficacious%20in%20elderly%20relapsed%20AML%20patients:%20Update%20from%20the%20ongoing%20BGBC003%20Phase%20II%20Trial%20(NCT02488408)&amp;author=S.%20Loges&amp;author=M.%20Heuser&amp;author=J..%20Chromik&amp;volume=136&amp;issue=suppl%201&amp;pages=14-14&amp;doi=10.1182/blood-2020-136566&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477436">
<span class="label">80.</span><cite>A clinical study of tomaralimab (OPN-305), a Toll-like receptor 2 (TLR-2) antibody, in heavily pre-treated transfusion dependent patients with lower risk myelodysplastic syndromes (MDS) that have received and failed on prior hypomethylating agent (HMA) therapy. Garcia-Manero G., Jabbour E., Konopleva M.., et al.  2018Blood. 132(suppl 1):798–798. doi: 10.1182/blood-2018-99-119805. <a href="https://doi.org/10.1182/blood-2018-99-119805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood-2018-99-119805</a></cite> [<a href="https://doi.org/10.1182/blood-2018-99-119805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20clinical%20study%20of%20tomaralimab%20(OPN-305),%20a%20Toll-like%20receptor%202%20(TLR-2)%20antibody,%20in%20heavily%20pre-treated%20transfusion%20dependent%20patients%20with%20lower%20risk%20myelodysplastic%20syndromes%20(MDS)%20that%20have%20received%20and%20failed%20on%20prior%20hypomethylating%20agent%20(HMA)%20therapy&amp;author=G.%20Garcia-Manero&amp;author=E.%20Jabbour&amp;author=M..%20Konopleva&amp;volume=132&amp;issue=suppl%201&amp;pages=798-798&amp;doi=10.1182/blood-2018-99-119805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477437">
<span class="label">81.</span><cite>Anti-CD123 CAR T-cell therapy for the treatment of myelodysplastic syndrome. Zhang W., Stevens B. M., Budde E. E.., et al.  2017Blood. 130(suppl 1):1917–1917. doi: 10.1182/blood.v130.suppl_1.1917.1917. <a href="https://doi.org/10.1182/blood.v130.suppl_1.1917.1917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1182/blood.v130.suppl_1.1917.1917</a></cite> [<a href="https://doi.org/10.1182/blood.v130.suppl_1.1917.1917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Anti-CD123%20CAR%20T-cell%20therapy%20for%20the%20treatment%20of%20myelodysplastic%20syndrome&amp;author=W.%20Zhang&amp;author=B.%20M.%20Stevens&amp;author=E.%20E..%20Budde&amp;volume=130&amp;issue=suppl%201&amp;pages=1917-1917&amp;doi=10.1182/blood.v130.suppl_1.1917.1917&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477438">
<span class="label">82.</span><cite>Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on dendritic cells of leukemic origin (DCleu) Ansprenger C., Amberger D.C., Schmetzer H.M. 2020Clin Immunol. 217:108467. doi: 10.1016/j.clim.2020.108467. <a href="https://doi.org/10.1016/j.clim.2020.108467" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.clim.2020.108467</a></cite> [<a href="https://doi.org/10.1016/j.clim.2020.108467" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32464186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Immunol&amp;title=Potential%20of%20immunotherapies%20in%20the%20mediation%20of%20antileukemic%20responses%20for%20patients%20with%20acute%20myeloid%20leukemia%20(AML)%20and%20myelodysplastic%20syndrome%20(MDS)%20-%20With%20a%20focus%20on%20dendritic%20cells%20of%20leukemic%20origin%20(DCleu)&amp;author=C.%20Ansprenger&amp;author=D.C.%20Amberger&amp;author=H.M.%20Schmetzer&amp;volume=217&amp;pages=108467&amp;pmid=32464186&amp;doi=10.1016/j.clim.2020.108467&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-477439">
<span class="label">83.</span><cite>Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Björklund A. T., Carlsten M., Sohlberg E.., et al.  2018Clin Cancer Res. 24(8):1834–1844. doi: 10.1158/1078-0432.CCR-17-3196. <a href="https://doi.org/10.1158/1078-0432.CCR-17-3196" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1158/1078-0432.CCR-17-3196</a></cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-3196" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29444931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Complete%20remission%20with%20reduction%20of%20high-risk%20clones%20following%20haploidentical%20NK-cell%20therapy%20against%20MDS%20and%20AML&amp;author=A.%20T.%20Bj%C3%B6rklund&amp;author=M.%20Carlsten&amp;author=E..%20Sohlberg&amp;volume=24&amp;issue=8&amp;pages=1834-1844&amp;pmid=29444931&amp;doi=10.1158/1078-0432.CCR-17-3196&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No patient data was directly utilized in this study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Clinical Hematology International are provided here courtesy of <strong>International Academy for Clinical Hematology</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.46989/001c.142956"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/chi_2025_7_3_142956.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (378.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12334995/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12334995/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12334995%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334995/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12334995/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12334995/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40786240/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12334995/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40786240/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12334995/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12334995/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="WL62vQt9ujfgJwpoS8xkCs7k5hm9ghBHzIm582JZjgJNvvQfmodfaPmndDNGktxe">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
